{"id":20390,"date":"2021-02-16T09:59:48","date_gmt":"2021-02-16T08:59:48","guid":{"rendered":"https:\/\/www.info.hazu.hr\/clanovi\/julius-stevo\/"},"modified":"2025-04-18T09:27:05","modified_gmt":"2025-04-18T07:27:05","slug":"julius-stevo","status":"publish","type":"clanovi","link":"https:\/\/www.info.hazu.hr\/en\/clanovi\/julius-stevo\/","title":{"rendered":"Julius Stevo"},"content":{"rendered":"<p>Academic titles:<\/p>\n<ul>\n<li>professor Doctor of Science<\/li>\n<\/ul>\n<p>Membership in the Academy:<\/p>\n<ul>\n<li>corresponding member &#8211; Department of Medical Sciences (5\/10\/2012 &#8211; 4\/11\/2025)<\/li>\n<\/ul>\n<hr \/>\n<h3>Curiculum Vitae<\/h3>\n<p><strong>Stevo Julius<\/strong>, a Croatian\u00a0<span class=\"Y2IQFc\" lang=\"en\">physician<\/span>, was born in Kovin, Serbia, in 1929, and at the age of seven moved with his family to Zagreb, where he graduated from elementary and secondary school. From the age of 14, he was a participant in the Anti-Fascist Struggle. He graduated from the Faculty of Medicine in Zagreb in 1953 and received his Doctorate in 1964. As an internal medicine specialist and assistant at the <span class=\"Y2IQFc\" lang=\"en\">Clinical Hospital Center Zagreb\u00a0<\/span>worked until 1964. Then he went to the University of the State of Michigan in Ann Arbor, USA, where he was head of the Department of Hypertension and a teacher for more than 40 years.<\/p>\n<p>Professor Julius&#8217;s research interest focuses on the field of pathophysiology of the early stages of arterial hypertension and metabolic syndrome. Today, he is an active professor emeritus of internal medicine and physiology.<\/p>\n<p>He is a guest professor at the Faculty of Medicine in Zagreb and Padua and an honorary doctor of science from the University of Gothenburg in Sweden. He is also an honorary member of the Australian, Croatian, European, Finnish, Hungary, Mexican, Spanish, Polish and Swedish Hypertension Society.<\/p>\n<p>Dr. Julius is the author of more than 400 published papers in the world&#8217;s leading journals and chapters in books, and his broad intellectual interest is evidenced by two books of memoirs: <em>Neither Red Nor Dead<\/em> and <em>Adventures in Hypertension<\/em>.<\/p>\n<p>He received the Lifetime Achievement Award and recognition\u00a0 of <em>The Corcoran Lectureship <\/em>Council for Hypertension Research by the American Society of Cardiology, <em>the William Harvey<\/em> Award <em>of the American Society of Hypertension<\/em>, <em>The Astra Cardiovascular Award<\/em> <em>of the International Society of Hypertension (ISH<\/em>),\u00a0 <em>Distinguished Faculty Award<\/em> from the University of the State of Michigan, the <em>Merit<\/em> Award\u00a0 of the National <em>Institutes of Health (NIH<\/em>) and honors from the European and Japanese Society for Hypertension. The International Society for Hypertension (ISH) has established the <em>Stevo Julius Award for Excellence in Hypertension Education<\/em> for the most respected educators.<\/p>\n<p>Professor Julius&#8217;s long-standing contribution to the research and treatment of arterial hypertension has left a lasting and deepest mark in world science, and is especially responsible for the development and improvement of research and treatment of arterial hypertension in Croatia.<\/p>\n<p>He was elected as a correspondent member of the Croatian Academy of Sciences and Arts in 2012. Stevo Julius died in 2025.<\/p>\n<p><a href=\"http:\/\/www.epi.umn.edu\/cvdepi\/bio-sketch\/julius-stevo\/\">Stevo Julius Personal Page<\/a><\/p>\n<hr \/>\n<h3>Bibliography<\/h3>\n<ol>\n<li>Julius S, Hranilovic B, Pokrajac N:\u00a0 Iz problematike hipertireoze.\u00a0 Medicinar pp. 331-343, 1950.<\/li>\n<\/ol>\n<ol>\n<li value=\"2\">Julius S:\u00a0 Dijagnostika Neurovegetativne Distonije.\u00a0 Med Glas, pp. 1-6, 1958.<\/li>\n<\/ol>\n<ol>\n<li value=\"3\">Julius S:\u00a0 O Nervnoj Regulaciji Krvne Slike.\u00a0 Neuropsihijatrija pp. 58-67, 1958.<\/li>\n<\/ol>\n<ol>\n<li value=\"4\">Conway J, Zweifler AJ, Julius S:\u00a0 The place of methyldopa in the treatment of severe hypertension.\u00a0 JAMA 186:266-268, 1963.<\/li>\n<\/ol>\n<ol>\n<li value=\"5\">McGinn NF, Harburg E, Julius S, McLeod JW:\u00a0 Psychological correlates of blood pressure.\u00a0 Psychol Bull 61:209-219, 1964.<\/li>\n<\/ol>\n<ol>\n<li value=\"6\">Julius S, McGinn NF, Harburg E, Hoobler SW:\u00a0 Comparison of various clinical measurements of blood pressure with the self-determination technique in normotensive college males.\u00a0 J Chronic Dis 17:391-396, 1964.<\/li>\n<\/ol>\n<ol>\n<li value=\"7\">Julius S, Harburg E, McGinn NF, Keyes J, Hoobler SW:\u00a0 Relation between casual blood pressure readings in youth and at age 40.\u00a0 J Chronic Dis 17:397-404, 1964.<\/li>\n<\/ol>\n<ol>\n<li value=\"8\">Harburg E, Julius S, McGinn NF, McLeod J, Hoobler SW:\u00a0 Personality traits and behavioral patterns associated with systolic blood pressure levels in college males.\u00a0 J Chronic Dis 17:405-414, 1964.<\/li>\n<\/ol>\n<ol>\n<li value=\"9\">McGinn NF, Harburg E, Julius S:\u00a0 Blood pressure reactivity and recall of treatment by parents.\u00a0 J Pers Soc Psychol 1:147-153, 1965.<\/li>\n<\/ol>\n<ol>\n<li value=\"10\">Julius S, Amery A, Whitlock SL, Conway J: \u00a0Influence of age on the hemodynamic response to exercise.\u00a0 Circulation 36:222-230, 1967.<\/li>\n<\/ol>\n<ol>\n<li value=\"11\">Amery A, Julius S, Whitlock LS, Conway J:\u00a0 Influence of hypertension on the hemodynamic response to exercise.\u00a0 Circulation, 36:231-237, 1967.<\/li>\n<\/ol>\n<ol>\n<li value=\"12\">Julius S, Stewart BH: \u00a0Diagnostic significance of abdominal murmurs.\u00a0 N Engl J Med 276:1175-1178, 1967.<\/li>\n<\/ol>\n<ol>\n<li value=\"13\">Conway J, Julius S, Amery A:\u00a0 Effect of blood pressure level on the hemodynamic response to exercise.\u00a0 Hypertension 16:79-85, 1968.<\/li>\n<\/ol>\n<ol>\n<li value=\"14\">Julius S, Conway J:\u00a0 Hemodynamic studies in patients with borderline blood pressure elevation.\u00a0 Circulation 38:282-288, 1968.<\/li>\n<\/ol>\n<ol>\n<li value=\"15\">Ferguson RJ, Faulkner JA, Julius S, Conway J:\u00a0 Comparison of cardiac output determined by CO2 rebreathing and dye-dilution methods.\u00a0 J Appl Physiol 25:450-454, 1968.<\/li>\n<\/ol>\n<ol>\n<li value=\"16\">Smet G, Hoobler SW, Sanbar S, Julius S:\u00a0 Clinical observations on a new antihypertensive drug, 2-(2,6-dichlorphenylamine)-2-imidazoline hydrochloride.\u00a0 Am Heart J 77:473-478, 1969.<\/li>\n<\/ol>\n<ol>\n<li value=\"17\">Sannerstedt R, Julius S, Conway J:\u00a0 Hemodynamic response to tilt and beta-adrenergic blockade in young patients with borderline hypertension.\u00a0 Circulation 42:1057-1064, 1970.<\/li>\n<\/ol>\n<ol>\n<li value=\"18\">Julius S, Pascual A, Reilly K, London R:\u00a0 Abnormalities of plasma volume in borderline hypertension.\u00a0 Arch Intern Med 127:116-119, 1971.<\/li>\n<\/ol>\n<ol>\n<li value=\"19\">Julius S, Schork MA:\u00a0 Borderline hypertension &#8211; a critical review.\u00a0 J Chronic Dis 23:723-754, 1971.<\/li>\n<\/ol>\n<ol>\n<li value=\"20\">Julius S, Pascual A, Sannerstedt R, Mitchell C:\u00a0 Relationship between cardiac output and peripheral resistance in borderline hypertension.\u00a0 Circulation 43:382-390, 1971.<\/li>\n<\/ol>\n<ol>\n<li value=\"21\">Julius S, Pascual AV, London R:\u00a0 Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension.\u00a0 Circulation 44:413-418, 1971.<\/li>\n<\/ol>\n<ol>\n<li value=\"22\"><a name=\"OLE_LINK2\"><\/a>Julius S, Pascual AV, Abbrecht P, London R:\u00a0 Effect of beta-adrenergic blockade on plasma volume in human subjects.\u00a0 Proc Soc Exp Biol Med 140:982-985, 1972.<\/li>\n<\/ol>\n<ol>\n<li value=\"23\">Pascual AV, Julius S:\u00a0 Short-term effectiveness and hemodynamic actions of guanadrel, a new sympatholytic drug.\u00a0 Curr Ther Res 14:333-341, 1972.<\/li>\n<\/ol>\n<ol>\n<li value=\"24\">Sannerstedt R, Julius S:\u00a0 Systemic haemodynamics in borderline arterial hypertension:\u00a0 Responses to static exercise before and under the influence of propranolol.\u00a0 Cardiovasc Res 6:398-403, 1972.<\/li>\n<\/ol>\n<ol>\n<li value=\"25\">Hansson L, Julius S, Sannerstedt R:\u00a0 Latent hypertension.\u00a0 Sartryck ur Lakartidningen 69:4011-4014, 1972.<\/li>\n<\/ol>\n<ol>\n<li value=\"26\">Hansson L, Hunyor SN, Julius S and Hoobler SW:\u00a0 Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management.\u00a0 Am Heart J 85:605-610, 1973.<\/li>\n<\/ol>\n<ol>\n<li value=\"27\">Hansson L, Pascual A, Julius S:\u00a0 Comparison of guanadrel and guanethidine.\u00a0 Clin Pharmacol Ther 14:204-208, 1973.<\/li>\n<\/ol>\n<ol>\n<li value=\"28\">Ellis CN, Julius S:\u00a0 Role of central blood volume in hyperkinetic borderline hypertension.\u00a0 Br Heart J 35:450-455, 1973.<\/li>\n<\/ol>\n<ol>\n<li value=\"29\">Ernst CB, Hansson L, Hunyor SN, Julius S:\u00a0 Stimulering av sinusnerverna med implanterad baropacer vid terapiresistent hypertension.\u00a0 (Stimulation of the sinus nerves with implanted baropacer in patients with therapy resistant hypertension.)\u00a0 Lakartidningen 70:1166-1168, 1973.<\/li>\n<\/ol>\n<ol>\n<li value=\"30\">Folkow B, Hallback M, Lundgren Y, Weiss L, Albrecht I, Julius S:\u00a0 Analysis of design and reactivity of series-coupled vascular sections in spontaneously hypertensive rats (SHR).\u00a0 Acta Physiol Scand 90:654-656, 1974.<\/li>\n<\/ol>\n<ol>\n<li value=\"31\">Julius S, Ellis CN, Pascual AV, Matice M, Hansson L, Hunyor SN, Sandler LN:\u00a0 Home blood pressure determination:\u00a0 value in borderline (&#8220;labile&#8221;) hypertension.\u00a0 JAMA 229:663-666, 1974.<\/li>\n<\/ol>\n<ol>\n<li value=\"32\">Hansson L, Zweifler AJ, Julius S, Hunyor SN:\u00a0 Hemodynamic effects of acute and prolonged b-adrenergic blockade in essential hypertension.\u00a0 Acta Med Scand 196:27-34, 1974.<\/li>\n<\/ol>\n<ol>\n<li value=\"33\">Hansson L, Zweifler AJ, Julius S, Ellis CN:\u00a0 Propranolol therapy in essential hypertension.\u00a0 Observations on predictability of therapeutic response.\u00a0 Int J Clin Pharmacol 10:79-89, 1974.<\/li>\n<\/ol>\n<ol>\n<li value=\"34\">Julius S, Hansson L:\u00a0 Hemodynamics of prehypertension and hypertension.\u00a0 Verh Dtsch Ges Inn Med 80:49-58, 1974.<\/li>\n<\/ol>\n<ol>\n<li value=\"35\">Julius S, Esler MD, Randall OS, Ellis CN:\u00a0 Neurogenic maintenance of peripheral resistance in borderline hypertension.\u00a0 Acta Physiol Lat Am 24:425-431, 1974.<\/li>\n<\/ol>\n<ol>\n<li value=\"36\">Hypertension-Stroke Cooperative Study Group.\u00a0 Effect of antihypertensive treatment on stroke recurrence.\u00a0 JAMA 229:409-418, 1974.<\/li>\n<\/ol>\n<ol>\n<li value=\"37\">Julius S, Esler MD, Randall OS:\u00a0 Role of the autonomic nervous system in mild human hypertension.\u00a0 Clin Sci Mol Med 48:243s-252s, 1975.<\/li>\n<\/ol>\n<ol>\n<li value=\"38\">Esler MD, Julius S, Randall OS, Ellis CN, Kashima T:\u00a0 Relation of renin status to neurogenic vascular resistance in borderline hypertension.\u00a0 Am J Cardiol 36:708-715, 1975.<\/li>\n<\/ol>\n<ol>\n<li value=\"39\">Julius S, Randall OS, Esler MD, Kashima T, Ellis CN, Bennett J:\u00a0 Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension.\u00a0 Circ Res 36-37 (Suppl. I):I-199-I-207, 1975.<\/li>\n<\/ol>\n<ol>\n<li value=\"40\">Albrecht I, Hallback M, Julius S, Lundgren Y, Stage L, Weiss L, Folkow B:\u00a0 Arterial pressure, cardiac output and systemic resistance before and after pithing in normotensive and spontaneously hypertensive rats.\u00a0 Acta Physiol Scand 94:378-385, 1975.<\/li>\n<\/ol>\n<ol>\n<li value=\"41\">Julius S, Esler M:\u00a0 Autonomic nervous cardiovascular regulation in borderline hypertension.\u00a0 Am J Cardiol 36:685-696, 1975.<\/li>\n<\/ol>\n<ol>\n<li value=\"42\">Esler M, Zweifler A, Randall O, Julius S, Bennett J, Rydelek P:\u00a0 Suppression of sympathetic nervous function in low-renin essential hypertension.\u00a0 Lancet 2:115-118, 1976.<\/li>\n<\/ol>\n<ol>\n<li value=\"43\">Julius S:\u00a0 Borderline hypertension:\u00a0 definitions and treatment.\u00a0 Cardiovasc Med 1:77-87, 1976.<\/li>\n<\/ol>\n<ol>\n<li value=\"44\">Julius S:\u00a0 Abnormalities of autonomic nervous control in borderline hypertension.\u00a0 Schweiz Med Wochenschr 106:1698-1705, 1976.<\/li>\n<\/ol>\n<ol>\n<li value=\"45\">Esler M, Julius S, Randall O, DeQuattro V, Zweifler A:\u00a0 High-renin essential hypertension:\u00a0 adrenergic cardiovascular correlates.\u00a0 Clin Sci Mol Med 51:181s-184s, 1976.<\/li>\n<\/ol>\n<ol>\n<li value=\"46\">Julius S, Esler M:\u00a0 Increased central blood volume:\u00a0 A possible pathophysiological factor in mild low-renin essential hypertension.\u00a0 Clin Sci Mol Med 51:207s-210s, 1976.<\/li>\n<\/ol>\n<ol>\n<li value=\"47\">Randall OS, Esler MD, Bulloch GF, Maisel AS, Ellis CN, Zweifler AJ, Julius S:\u00a0 Relationship of age and blood pressure to baroreflex sensitivity and arterial compliance in man.\u00a0 Clin Sci Mol Med 51:357s-360s, 1976.<\/li>\n<\/ol>\n<ol>\n<li value=\"48\">Julius S, Esler M, Hansson L, Zweifler AJ: Dissociation of the renin lowering and antihypertensive actions of propranolol.\u00a0 Advances in Clin Pharmacology 11:33-41, 1976.<\/li>\n<\/ol>\n<ol>\n<li value=\"49\">Esler M, Julius S, Zweifler A, Randall O, Harburg E, Gardiner H, DeQuattro V.\u00a0 Mild high-renin essential hypertension:\u00a0 Neurogenic human hypertension?\u00a0 N Engl J Med 296:405-411, 1977.<\/li>\n<\/ol>\n<ol>\n<li value=\"50\">Julius S:\u00a0 Borderline hypertension:\u00a0 an overview.\u00a0 Med Clin North Am 61:495-511, 1977.<\/li>\n<\/ol>\n<ol>\n<li value=\"51\">Simon G, Kiowski W, Julius S:\u00a0 Effect of beta adrenoceptor antagonists on baroreceptor reflex sensitivity in hypertension.\u00a0 Clin Pharmacol Ther 22:293-298, 1977.<\/li>\n<\/ol>\n<ol>\n<li value=\"52\">Julius S, Esler M: Patterns of neurogenic involvement in borderline and essential hypertension.\u00a0 Progress in Brain Research 47:251-62, 1977.<\/li>\n<\/ol>\n<ol>\n<li value=\"53\">Julius S:\u00a0 Clinical and physiological significance of borderline hypertension at youth.\u00a0 Ped Clin North Am 25:35-45, 1978.<\/li>\n<\/ol>\n<ol>\n<li value=\"54\">Simon G, Kiowski W, Julius S:\u00a0 Antihypertensive and \u00df-adrenoceptor antagonist action of timolol.\u00a0 Clin Pharmacol Ther 23:152-157, 1978.<\/li>\n<\/ol>\n<ol>\n<li value=\"55\">Randall O, Esler M, Culp B, Julius S and Zweifler A:\u00a0 Determinants of baroreflex sensitivity in man.\u00a0 J Lab Clin Med 91:514-519, 1978.<\/li>\n<\/ol>\n<ol>\n<li value=\"56\">Esler M, Zweifler A, Randall O, Julius S, DeQuattro V:\u00a0 The determinants of plasma-renin activity in essential hypertension.\u00a0 Ann Int Med 88:746-752, 1978.<\/li>\n<\/ol>\n<ol>\n<li value=\"57\">Kiowski W, Julius S:\u00a0 Renin response to stimulation of cardiopulmonary mechanoreceptors in man.\u00a0 J Clin Invest 62:656-663, 1978.<\/li>\n<\/ol>\n<ol>\n<li value=\"58\">Simon G, Kiowski W, Julius S:\u00a0 Left ventricular performance during antihypertensive therapy with timolol.\u00a0 Curr Ther Res 25:626-632, 1979.<\/li>\n<\/ol>\n<ol>\n<li value=\"59\">Simon G, Kiowski W, Julius S:\u00a0 Effect of systemic autonomic inhibition on the hemodynamic response to antihypertensive therapy with timolol.\u00a0 Int J Clin Pharmacol Biopharm 17:507-510, 1979<\/li>\n<\/ol>\n<ol>\n<li value=\"60\">Shapiro AP, Benson H, Chobanian AV, Herd JA, Julius S, Kaplan N, Lazarus RS, Ostfeld AM, Syme SL. The role of stress in hypertension.\u00a0 J Human Stress 5(2):7-26, 1979.<\/li>\n<\/ol>\n<ol>\n<li value=\"61\">Nicholls MG, Kiowski W, Zweifler AJ, Julius S, Schork MA, Greenhouse J:\u00a0 Plasma norepinephrine variations with dietary sodium intake.\u00a0 Hypertension 2:29-32, 1980.<\/li>\n<\/ol>\n<ol>\n<li value=\"62\">Julius S, Hansson L, Andren L, Gudbrandsson T, Sivertsson R, Svensson A:\u00a0 Borderline hypertension (Hypertension Seminars at Ostra Hospital, Goteborg, Sweden).\u00a0 Acta med Scand 208:481-489, 1980.<\/li>\n<\/ol>\n<ol>\n<li value=\"63\">Zweifler AJ, Julius S, Nicholls MG:\u00a0 Efficacy of an oral angiotensin converting enzyme inhibitor (captopril) in severe hypertension.\u00a0 Arch Int Med 141:907-910, 1981.<\/li>\n<\/ol>\n<ol>\n<li value=\"64\">Nicholls MG, Julius S, Zweifler AJ:\u00a0 Withdrawal of endogenous sympathetic drive lowers blood pressure in primary aldosteronism.\u00a0 Clin Endocrinol 15:253-258, 1981.<\/li>\n<\/ol>\n<ol>\n<li value=\"65\">Kiowski W, Randall OS, Steffens TG, Julius S:\u00a0 Reliability of echocardiography in assessing cardiac output.\u00a0 Klin Wochenschr 59:1115-1120, 1981.<\/li>\n<\/ol>\n<ol>\n<li value=\"66\">Nicholls MG, Espiner EA, Miles KD, Zweifler AJ, Julius S:\u00a0 Evidence against an interaction of angiotensin II with the sympathetic nervous system in man.\u00a0 Clin Endocrinol 15:423-430, 1981.<\/li>\n<\/ol>\n<ol>\n<li value=\"67\">Victery W, Vander A, Shulak J, Shoeps P, Julius S:\u00a0 Lead hypertension and the renin-angiotensin system in rats.\u00a0 J Lab Clin Med 99:354-362, 1982.<\/li>\n<\/ol>\n<ol>\n<li value=\"68\">Zweifler A, Julius S:\u00a0 Increased platelet catecholamine content in pheochromocytoma.\u00a0 A diagnostic test in patients with elevated plasma catecholamines.\u00a0 N Engl J Med 306:890-894, 1982.<\/li>\n<\/ol>\n<ol>\n<li value=\"69\">Cottier C, Julius S, Gajendragadkar SV, Schork MA:\u00a0 Usefulness of home BP determination in treating borderline hypertension.\u00a0 JAMA 248:555-558, 1982.<\/li>\n<\/ol>\n<ol>\n<li value=\"70\">Julius S, Sanchez R, Malayan S, Hamlin M, Elkins M, Brant D, Bohr DF:\u00a0 Sustained blood pressure elevation to lower body compression in pigs and dogs.\u00a0 Hypertension 4:782-788, 1982.<\/li>\n<\/ol>\n<ol>\n<li value=\"71\">Cottier C, Julius S:\u00a0 Use of clonidine and propranolol as monotherapy in borderline hypertension.\u00a0 Chest 83:422-425, 1983.<\/li>\n<\/ol>\n<ol>\n<li value=\"72\">Ibsen H, Egan B, Osterziel K, Julius S:\u00a0 Reflex hemodynamic adjustments and baroreflex sensitivity during converting enzyme inhibition with MK-421 in normal man.\u00a0 Hypertension 5 (Suppl. I): I-184-I-191, 1983.<\/li>\n<\/ol>\n<ol>\n<li value=\"73\">Egan B, Julius S. Borderline hypertension.\u00a0 Primary Care; Clinics in Office Practice 10(1):99-113, 1983.<\/li>\n<\/ol>\n<ol>\n<li value=\"74\">Julius S, Cottier C, Egan B, Ibsen H, Kiowski W:\u00a0 Cardiopulmonary mechanoreceptors and renin release in humans.\u00a0 Federation Proc 42:2703-2708, 1983.<\/li>\n<\/ol>\n<ol>\n<li value=\"75\">Egan BM, Julius S, Cottier C, Osterziel KJ, Ibsen H:\u00a0 The role of cardiovascular receptors on the neural regulation of renin release in normal man.\u00a0 Hypertension 5:779-786, 1983.<\/li>\n<\/ol>\n<ol>\n<li value=\"76\">Ibsen H, Egan B, Julius S:\u00a0 Baroreflex sensitivity during converting enzyme inhibition with Enalapril (MK-421) in normal man.\u00a0 J Hypertension 1 (suppl 2):222-224, 1983.<\/li>\n<\/ol>\n<ol>\n<li value=\"77\">Ferguson JJ, Julius S, Randall OS:\u00a0 Stroke volume-pulse pressure relationships in borderline hypertension:\u00a0 A possible indicator of decreased arterial compliance.\u00a0 J Hypertension 2 (suppl. 3):397-399, 1984.<\/li>\n<\/ol>\n<ol>\n<li value=\"78\">Weder AB, Torretti BA, Julius S:\u00a0 Racial differences in erythrocyte cation transport.\u00a0 Hypertension 6:115-123, 1984.<\/li>\n<\/ol>\n<ol>\n<li value=\"79\">Colfer HT, Cottier C, Sanchez R, Julius S:\u00a0 Role of cardiac factors in the initial hypotensive action by beta-adrenoreceptor blocking agents.\u00a0 Hypertension 6:145-151, 1984.<\/li>\n<\/ol>\n<ol>\n<li value=\"80\">Ibsen H, Julius S:\u00a0 Pharmacologic tools for assessment of adrenergic nerve activity in human hypertension.\u00a0 Federation Proc 43:67-71, 1984.<\/li>\n<\/ol>\n<ol>\n<li value=\"81\">Cottier C, Shapiro K, Julius S:\u00a0 Treatment of mild hypertension with progressive muscle relaxation:\u00a0 Predictive value of indices of sympathetic tone.\u00a0 Arch Int Med 144:1954-1958, 1984.<\/li>\n<\/ol>\n<ol>\n<li value=\"82\">Osterziel KJ, Julius S, Brant D:\u00a0 Blood pressure elevation during hindquarter compression in dogs is neurogenic.\u00a0 J Hypertension 4:411-417, 1984.<\/li>\n<\/ol>\n<ol>\n<li value=\"83\">Egan B, Grekin R, Ibsen H, Osterziel K, Julius S:\u00a0 The role of cardiopulmonary mechanoreceptors in the ADH release in normal man.\u00a0 Hypertension 6:832-836, 1984.<\/li>\n<\/ol>\n<ol>\n<li value=\"84\">Weder AB, Julius S:\u00a0 Behavior, blood pressure variability and hypertension.\u00a0 Psychosom Med 47:406-414, 1985.<\/li>\n<\/ol>\n<ol>\n<li value=\"85\">Egan B, Neubig R, Schneider R, Julius S:\u00a0 Methods for measuring vascular and nonvascular alpha-receptor sensitivity in humans.\u00a0 J Cardiovasc Pharmacol 7(Suppl 6):S153-S158, 1985.<\/li>\n<\/ol>\n<ol>\n<li value=\"86\">Egan B, Julius S:\u00a0 Vascular hypertrophy in borderline hypertension:\u00a0 Relationship to blood pressure and sympathetic drive.\u00a0 Clin Exp Hypertension &#8211; Theory and Practice A7:243-255, 1985.<\/li>\n<\/ol>\n<ol>\n<li value=\"87\">Egan B, Neubig R, Julius S:\u00a0 Pharmacologic reduction of sympathetic drive increases platelet alpha2-receptor number.\u00a0 Clin Pharm Therap 38:519-524, 1985.<\/li>\n<\/ol>\n<ol>\n<li value=\"88\">Julius S, Johnson EH:\u00a0 Stress, autonomic hyperactivity and essential hypertension:\u00a0 An enigma.\u00a0 J Hypertension 3(suppl 4):S11-S18, 1985.<\/li>\n<\/ol>\n<ol>\n<li value=\"89\">Schneider RH, Egan BM, Johnson EH, Drobny H, Julius S:\u00a0 Anger and anxiety in borderline hypertension.\u00a0 Psychosom Med 48:242-248, 1986.<\/li>\n<\/ol>\n<ol>\n<li value=\"90\">Fitzpatrick MA, Hinderliter AL, Egan BM, Julius S:\u00a0 Decreased venous distensibility and reduced renin responsiveness in hypertension.\u00a0 Hypertension 8(Suppl II):II-36-II-43, 1986.<\/li>\n<\/ol>\n<ol>\n<li value=\"91\">Julius S:\u00a0 The emerging field of borderline hypertension.\u00a0 J Cardiovasc Pharmacol 8(Suppl 5):S4-S7, 1986.<\/li>\n<\/ol>\n<ol>\n<li value=\"92\">Julius S, Sanchez R, Brant D:\u00a0 Pressure increase to external hind quarter compression in dogs:\u00a0 A facultative regulatory response.\u00a0 J Hypertension 4(suppl 6):\u00a0 S54-S56, 1986.<\/li>\n<\/ol>\n<ol>\n<li value=\"93\">Weder AB, Fitzpatrick MA, Torretti BA, Hinderliter AL, Egan BM, Julius S:\u00a0 Red blood cell lithium-sodium countertransport as a genetic marker in essential hypertension.\u00a0 J Hypertension 4(suppl 6): S373-375, 1986.<\/li>\n<\/ol>\n<ol>\n<li value=\"94\">Egan B, Fitzpatrick MA, Julius S:\u00a0 The heart and the regulation of renin.\u00a0 Circulation 75(Suppl I):I-130-I-133, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"95\">Sanchez RA, Marco EJ, Oliveri C, Otero FJ, DeGrossi O, Moledo LI, Julius S:\u00a0 Role of cardiopulmonary mechanoreceptors in the postural regulation of renin.\u00a0 Am J Cardiol 59:881-886, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"96\">Hinderliter AL, Fitzpatrick MA, Schork N, Julius S:\u00a0 Research utility of noninvasive methods for measurement of cardiac output.\u00a0 Clin Pharmacol Ther 41:419-425, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"97\">Weder AB, Fitzpatrick MA, Torretti BA, Hinderliter AL, Egan BM, Julius S:\u00a0 Red blood cell Li+-Na+\u00a0countertransport, Na+-K+\u00a0cotransport, and the hemodynamics of hypertension.\u00a0 Hypertension 9 (No. 5):459-466, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"98\">Julius S: \u00a0Role of the sympathetic nervous system in the pathophysiology of cardiovascular disease.\u00a0 American Heart Journal 114 (No. 1, Part 2):232-234, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"99\">Egan B, Panis R, Hinderliter A, Schork N, Julius S:\u00a0 Mechanism of increased alpha-adrenergic vasoconstriction in human essential hypertension.\u00a0 J Clin Invest 80:812-817, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"100\">Shapiro AP, Alderman MH, Clarkson TB, Furberg CD, Jesse MJ, Julius S, Miller RE, Pitt B:\u00a0 Task Force 4:\u00a0 Behavioral consequences of hypertension and antihypertensive therapy.\u00a0 Conference on Behavioral Medicine and Cardiovascular Disease; Sea Island Proceedings.\u00a0 Circulation 76 (Suppl 1):I-101 &#8211; I-103, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"101\">Zipes DP, Levy MN, Cobb LA, Julius S, Kaufman PG, Miller NE, Verrier RL:\u00a0 Task Force 2:\u00a0 Sudden cardiac death.\u00a0 Neural-cardiac interactions.\u00a0 Conference on Behavioral Medicine and Cardiovascular Disease; Sea Island Proceedings.\u00a0 Circulation 76(Suppl 1):I-202 &#8211; I-207, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"102\">Julius S:\u00a0 Discussion on the search for an ideal vasodilator:\u00a0 A hemodynamic perspective.\u00a0 J. Cardiovasc. Pharm 10 (Suppl. 1):S149-S153, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"103\">Schneider RH, Julius S, Moss GE, Dielman TE, Zweifler AJ, Karunas R:\u00a0 New markers for Type A behavior:\u00a0 pupil size and platelet epinephrine.\u00a0 Psychosom Med 49:579-590. , 1987<\/li>\n<\/ol>\n<ol>\n<li value=\"104\">Weder AB, Sekkarie MA, Takiyyuddin M, Schork NJ and Julius S:\u00a0 Antihypertensive and hypotensive effects of atrial natriuretic factor in men.\u00a0 Hypertension 10:582-589, 1987.<\/li>\n<\/ol>\n<ol>\n<li value=\"105\">Julius S:\u00a0 Editorial Review:\u00a0 The blood pressure seeking properties of the central nervous system.\u00a0 J Hypertension 6:177-185, 1988.<\/li>\n<\/ol>\n<ol>\n<li value=\"106\">Egan B, Conlon ME, Campbell R, Schork N, Zweifler A, Julius S:\u00a0 Effects of ketanserin on blood pressure and platelet aggregation in elderly men with mild hypertension.\u00a0 Am J Hypertens 1:324S-330S, 1988.<\/li>\n<\/ol>\n<ol>\n<li value=\"107\">Julius S, Brant D:\u00a0 Hemodynamic plasticity during hindquarter compression.\u00a0 Acta Physiologica Scandinavica 133(Supp 571):107-116, 1988.<\/li>\n<\/ol>\n<ol>\n<li value=\"108\">Julius S, Schork N, Schork A:\u00a0 Sympathetic hyperactivity in early stages of hypertension:\u00a0 The Ann Arbor data set.\u00a0 J Cardiovascular Pharmacology 12(Suppl. 3):S121-S129, 1988.<\/li>\n<\/ol>\n<ol>\n<li value=\"109\">Julius S:\u00a0 Transition from high cardiac output to elevated vascular resistance in hypertension.\u00a0 American Heart Journal 116(No. 2,Part 2):600-606, 1988.<\/li>\n<\/ol>\n<ol>\n<li value=\"110\">Julius S:\u00a0 Interaction between renin and the autonomic nervous system in hypertension.\u00a0 American Heart Journal 116 (No. 2,Part 2):611-616, 1988.<\/li>\n<\/ol>\n<ol>\n<li value=\"111\">Sambhi MP, Chobanian AV, Julius S, Noth RH, Borhani NO, Perry HM Jr:\u00a0 Mild Hypertension.\u00a0 American J Med 85(5):675-696, 1988.<\/li>\n<\/ol>\n<ol>\n<li value=\"112\">Weder AB, Takiyyuddin M, Sekkarie MA and Julius S:\u00a0 Behavior and hypertension:\u00a0 A pathophysiologic puzzle.\u00a0 J Hypertension 7(Suppl 1):S13-S17, 1989.<\/li>\n<\/ol>\n<ol>\n<li value=\"113\">Julius S, Li Y, Brant D, Krause L, Buda A:\u00a0 Neurogenic pressor episodes fail to cause hypertension, but do induce cardiac hypertrophy.\u00a0 Hypertension 13:422-429, 1989.<\/li>\n<\/ol>\n<ol>\n<li value=\"114\">Schneider RH, Julius S, Karunas R:\u00a0 Ambulatory blood pressure monitoring and laboratory reactivity in Type A behavior and components.\u00a0 Psychosomatic Medicine 51:290-305,1989.<\/li>\n<\/ol>\n<ol>\n<li value=\"115\">Mejia A, Julius S:\u00a0 Practical utility of blood pressure readings obtained by self-determination.\u00a0 J Hypertension 7(Suppl 3):S53-S57, 1989.<\/li>\n<\/ol>\n<ol>\n<li value=\"116\">Julius S, Weder AB:\u00a0 Brain and the regulation of blood pressure:\u00a0 A hemodynamic perspective.\u00a0 Clinical and Experimental Hypertension A11(Suppl.1):1-19, 1989.<\/li>\n<\/ol>\n<ol>\n<li value=\"117\">Julius S, Gupta R:\u00a0 Angiotensin converting enzyme inhibitors and the progress of antihypertensive treatment.\u00a0 J Hypertension 7(Suppl 5):S23-S27, 1989.<\/li>\n<\/ol>\n<ol>\n<li value=\"118\">Petrin J, Egan BM, Julius S:\u00a0 Increased beta-adrenergic tone enhances arterial compliance in hyperkinetic borderline hypertension.\u00a0 J Hypertension 7 (Suppl 6):S78-S79), 1989.<\/li>\n<\/ol>\n<ol>\n<li value=\"119\">Schork NJ, Weder AB, Schork MA, Bassett DR, Julius S:\u00a0 Disease entities, mixed multi-normal distributions, and the role of the hyperkinetic state in the pathogenesis of hypertension.\u00a0 Statistics and Medicine 9:301-314, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"120\">Julius S:\u00a0 Hemodynamic and neurohumoral evidence of multifaceted pathophysiology in human hypertension.\u00a0 J Cardiovascular Pharmacology 15(Suppl. 5):S53-S58, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"121\">Mejia AD, Julius S, Jones KA, Schork NJ, Kneisley J:\u00a0 The Tecumseh blood pressure study:\u00a0 Normative data on BP self-determination.\u00a0 Arch Int Med 150(6):1209-1213, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"122\">Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K:\u00a0 The association of borderline hypertension with target organ changes and higher coronary risk.\u00a0 Tecumseh Blood Pressure Study.\u00a0 JAMA 264:354-358, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"123\">Julius S:\u00a0 Are different hemodynamic patterns of antihypertensive drugs clinically important?\u00a0 Eur J Clin Pharmacol 38:S125-S128, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"124\">Gupta RK, Kjeldsen SE, Krause L, Kneisley J, E Posvar, Weder AB, Julius S:\u00a0 Hemodynamic effects of quinapril, a novel angiotensin-converting enzyme inhibitor.\u00a0 Clin Pharmacol &amp; Ther 48:41-49, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"125\">Kneisley J, Schork N, Julius S:\u00a0 Predictors of blood pressure and hypertension in Tecumseh, Michigan.\u00a0 Clin Exp Hypertension &#8211; Theory and Practice A12(5):693-708, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"126\">Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, Johnson E, Petrin J, Sekkarie MA, Kjeldsen SE, Schmouder R, Gupta R, Ferraro J, Nazzaro P, Weissfeld J:\u00a0 &#8220;White coat&#8221; versus &#8220;sustained&#8221; borderline hypertension in Tecumseh, Michigan.\u00a0 Hypertension 16:617-623, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"127\">Julius S:\u00a0 Changing role of the autonomic nervous system in human hypertension.\u00a0 J Hypertens 8(7):S59-S65, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"128\">Julius S.\u00a0 Validation of non-invasive measurement of cardiac output.\u00a0 The Ann Arbor experience.\u00a0 Eur Heart Journal 11(Suppl I):144-147, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"129\">Buhler FR, Julius S, Reaven GM: A new dimension in hypertension: role of insulin resistance.\u00a0 J Cardio Pharmacology 15(Suppl 5):S1-3, 1990.<\/li>\n<\/ol>\n<ol>\n<li value=\"130\">Julius S, Krause L, Schork NJ, Mejia AD, Jones KA, van de Ven C, Johnson EH, Sekkarie MA, Kjeldsen SE, Petrin J, Schmouder R, Gupta R, Ferraro J, Nazzaro P, Weissfeld J:\u00a0 Hyperkinetic borderline hypertension in Tecumseh, Michigan.\u00a0 J Hypertension 9:77-84, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"131\">Gupta RK, Kjeldsen SE, Motley E, Weder AB, Zweifler AJ, Julius S:\u00a0 Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor.\u00a0 J Cardio Pharmacology 17:13-19, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"132\">Julius S, Jones K, Schork N, Johnson E, Krause L, Nazzaro P, Zemva A:\u00a0 Independence of pressure reactivity from pressure levels in Tecumseh, Michigan.\u00a0 Hypertension 17(Suppl III):III-12-III-21, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"133\">Weder AB, Schork NJ, Krause L, Julius S:\u00a0 Red blood cell lithium-sodium countertransport in the Tecumseh blood pressure study.\u00a0 Hypertension 17:652-660, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"134\">Julius S:\u00a0 Autonomic nervous system dysregulation in human hypertension.\u00a0 Am J Cardiol 67:3B-7B, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"135\">Julius S:\u00a0 More on &#8220;white coat&#8221; hypertension.\u00a0 Letters to the Editor.\u00a0 Hypertension 17:826-827, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"136\">Weder AB, Schork NJ, Julius S:\u00a0 Linkage of MN locus and erythrocyte lithium-sodium countertransport in Tecumseh, Michigan.\u00a0 Hypertension 17:977-981, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"137\">Julius S, Li Y, Brant D, Krause L, Taylor D:\u00a0 Quinapril, an angiotensin converting enzyme inhibitor, prevents cardiac hypertrophy during episodic hypertension.\u00a0 Hypertension 17:1161-1166, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"138\">Buda AJ, Li Y, Brant D, Krause L, Julius S:\u00a0 Changes in left ventricular diastolic filling during the development of left ventricular hypertrophy:\u00a0 Observations using Doppler echocardiography in a unique canine model.\u00a0 Am Heart J 121:1759-1767, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"139\">Julius S, Gudbrandsson T, Jamerson K, Shahab ST, Andersson O:\u00a0 Hypothesis.\u00a0 The hemodynamic link between insulin resistance and hypertension.\u00a0 J Hypertension 9(11):983-986, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"140\">Julius S:\u00a0 Autonomic nervous dysfunction in essential hypertension.\u00a0 Diabetes Care 14 (3):249-259, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"141\">Jamerson K, Julius S:\u00a0 Predictors of blood pressure and hypertension.\u00a0 General principles.\u00a0 Am J Hypertens 4:598S-602S, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"142\">Julius S:\u00a0 Clinical implications of pathophysiologic changes in the midlife hypertensive patient.\u00a0 Am. Heart J 122:886-891, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"143\">Julius S:\u00a0 Home blood pressure monitoring:\u00a0 Advantages and limitations.\u00a0 J Hypertens 9 (Suppl 3):S41-S46, 1991.<\/li>\n<\/ol>\n<ol>\n<li value=\"144\">Kjeldsen S, Gupta R, Krause L, Weder A, Julius S:\u00a0 Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril.\u00a0 Am Heart J 123:1433-1438, 1992.<\/li>\n<\/ol>\n<ol>\n<li value=\"145\">Julius S, Gudbrandsson T, Jamerson K, Andersson O:\u00a0 The interconnection between sympathetics, microcirculation and insulin resistance in hypertension.\u00a0 Blood Pressure 1: 9-19, 1992.<\/li>\n<\/ol>\n<ol>\n<li value=\"146\">Gudbrandsson T, Julius S, Krause L, Jamerson K, Randall O, Schork N, Weder, A:\u00a0 Correlates of the estimated arterial compliance in the population of Tecumseh, Michigan.\u00a0 Blood Pressure 1: 27-34, 1992.<\/li>\n<\/ol>\n<ol>\n<li value=\"147\">Jamerson K, Schork N, Julius S:\u00a0 Effect of home blood pressure and gender on estimates of the familial aggregation of blood pressure; the Tecumseh blood pressure study.\u00a0 Hypertension 20,3: 314-318, 1992.<\/li>\n<\/ol>\n<ol>\n<li value=\"148\">Julius S:\u00a0 Assessment of autonomic nervous function in human hypertension.\u00a0 (Invited editorial) Current Opinion In Nephrology and Hypertension 1, No. 2:299-305, 1992.<\/li>\n<\/ol>\n<ol>\n<li value=\"149\">Julius S, Gudbrandsson T:\u00a0 Early association of sympathetic overactivity, hypertension, insulin resistance and coronary risk.\u00a0 J Cardiovascular Pharmacology 20(Suppl. 8):S40-S48, 1992.<\/li>\n<\/ol>\n<ol>\n<li value=\"150\">Julius S, Jamerson KA, Gudbrandsson T, Schork N:\u00a0 White coat hypertension:\u00a0 A follow-up.\u00a0 Clin Exp Hypertens A14:45-53, 1992.<\/li>\n<\/ol>\n<ol>\n<li value=\"151\">Julius S (Editorial):\u00a0 Insulin, Insulin Resistance and Blood Pressure Elevation.\u00a0 Archives of Internal Medicine 153\/3:290-291, 1993.<\/li>\n<\/ol>\n<ol>\n<li value=\"152\">Julius S:\u00a0 Treatment of hypertension.\u00a0 Blood Pressure 1 (Suppl 4):43-47, 1992.<\/li>\n<\/ol>\n<ol>\n<li value=\"153\">Kjeldsen SE, Moan A, Petrin J, Weder A, Zweifler A, Julius S:\u00a0 Evaluation of self-measured home vs. clinic intra-arterial blood pressure.\u00a0 Blood Pressure 2, 1:28-34, 1993.<\/li>\n<\/ol>\n<ol>\n<li value=\"154\">Jamerson KA, Julius S, Gudbrandsson T, Andersson O, Brant DO:\u00a0 Reflex sympathetic activation induces acute insulin resistance in the human forearm.\u00a0 Hypertension 21, 5:618-623, 1993.<\/li>\n<\/ol>\n<ol>\n<li value=\"155\">Julius S:\u00a0 (Corcoran Lecture) Sympathetic hyperactivity and coronary risk in hypertension, Hypertension 21, 6:886-893, 1993.<\/li>\n<\/ol>\n<ol>\n<li value=\"156\">Kjeldsen S, Petrin J, Weder A, Julius S:\u00a0 Contrasting effects of epinephrine on forearm hemodynamics and arterial plasma norepinephrine.\u00a0 Am J Hypertension 6, 5:369-375, 1993.<\/li>\n<\/ol>\n<ol>\n<li value=\"157\">Julius S, Jamerson KA:\u00a0 Sympathetic vasomotor tone, hemodynamics and insulin resistance in hypertension, High Blood Pressure &amp; Cardiovascular Prevention 2:153-160, 1993.<\/li>\n<\/ol>\n<ol>\n<li value=\"158\">Zanchetti A (Chairman), Chalmers JP, Arakawa K, Gyarfas I, Hamet P, Hansson L, Julius S, MacMahon S, Mancia G, M\u00e9nard J, Omae T, Reid J, Safar M:\u00a0 The 1993 guidelines for the management of mild hypertension: memorandum from a WHO\/ISH meeting, Blood Pressure 2:86-100, 1993.<\/li>\n<\/ol>\n<ol>\n<li value=\"159\">Kingwell BA, Krause L, Julius S:\u00a0 The effect of hypertensive episodes and cardiac hypertrophy on the canine cardiac baroreflex.\u00a0 Clin and Exp Pharm and Physiology 21:31-39, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"160\">Shahab ST, Gudbrandsson T, Jamerson KA, Julius S:\u00a0 Isolated &#8220;home hypertension&#8221; in Tecumseh, Michigan, Croatian Medical Journal 34(4):325-331, 1993.<\/li>\n<\/ol>\n<ol>\n<li value=\"161\">Julius S:\u00a0 Abnormalities of autonomic nervous control in human hypertension, Cardiovascular Drugs and Therapy 8:11-20, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"162\">Kjeldsen SE, Zweifler AJ, Petrin J, Weder AB, Julius S:\u00a0 Sympathetic nervous system involvement in essential hypertension: increased platelet noradrenaline coincides with decreased \u00df-adrenoreceptor responsiveness, Blood Pressure 3:164-171, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"163\">Smith S, Julius S, Jamerson K, Amerena J, Schork N:\u00a0 Hematocrit levels and physiologic factors in relationship to cardiovascular risk in Tecumseh, Michigan.\u00a0 J Hypertens 12:455-462, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"164\">Gudbrandsson T, Julius S, Jamerson K, Smith S, Krause L, Schork N:\u00a0 Recreational exercise and cardiovascular status in the rural community of Tecumseh, Michigan, Blood Pressure 3:178-184, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"165\">Julius S, Jamerson K:\u00a0 Sympathetics, insulin resistance and coronary risk in hypertension: the \u2018chicken and egg\u2019 question.\u00a0 J Hypertens 12:495-502, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"166\">Marcus R, Krause L, Weder AB, Dominguez-Mejia A, Schork NJ, Julius S:\u00a0 Sex-specific determinants of increased left ventricular mass in the Tecumseh blood pressure study.\u00a0 Circulation 90:928-936, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"167\">Jamerson K, Smith SD, Amerena JV, Grant E, Julius S:\u00a0 Vasoconstriction with norepinephrine causes less forearm insulin resistance than a reflex sympathetic vasoconstriction.\u00a0 Hypertension 23(6):1006-1011, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"168\">Julius S:\u00a0 La interrelaci\u00f3n entre hiperactividad simp\u00e1tica y resistencia a la insulina en la hipertensi\u00f3n humana; un dilema fisiopatol\u00f3gico.\u00a0 J Hypertens, Edici\u00f3n Espa\u00f1ola 1(Suppl 1):S27-S34, 1994.<\/li>\n<\/ol>\n<ol>\n<li value=\"169\">Julius S:\u00a0 The defense reaction: a common denominator of coronary risk and blood pressure in neurogenic hypertension?\u00a0 Clin and Exper Hypertension 17(1&amp;2):375-386, 1995.<\/li>\n<\/ol>\n<ol>\n<li value=\"170\">Julius S:\u00a0 Sympathetic overactivity and the pathophysiology of the coronary risk in hypertension.\u00a0 Cardiovascular Risk Factors 5(Suppl 1):2-10, 1995.<\/li>\n<\/ol>\n<ol>\n<li value=\"171\">Kjeldsen SE, Weder AB, Egan B, Neubig R, Zweifler AJ, Julius S:\u00a0 Effect of circulating epinephrine on platelet function and hematocrit.\u00a0 Hypertension 25(5):1096-1105, 1995.<\/li>\n<\/ol>\n<ol>\n<li value=\"172\">Amerena J, Julius S:\u00a0 The role of the autonomic nervous system in hypertension.\u00a0 (An invited review) Hypertension Research 18(2):99-110, 1995.<\/li>\n<\/ol>\n<ol>\n<li value=\"173\">Julius S, Nesbitt S:\u00a0 Sympathetic nervous system as a coronary risk factor in hypertension.\u00a0 Cardiologia 41(4):309-317, 1996.<\/li>\n<\/ol>\n<ol>\n<li value=\"174\">Julius S:\u00a0 The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension.\u00a0 Clin and Exp Hypertens 18(3&amp;4):305-321, 1996.<\/li>\n<\/ol>\n<ol>\n<li value=\"175\">Jamerson J, Nesbitt S, Amerena J, Grant E, Julius S:\u00a0 Angiotensin mediates forearm glucose uptake by hemodynamic rather than direct effects.\u00a0 Hypertension 27:854-858 1996.<\/li>\n<\/ol>\n<ol>\n<li value=\"176\">Kjeldsen SE, Moan A, Petrin J, Weder AB, Julius S:\u00a0 Effects of increased arterial epinephrine on insulin, glucose and phosphate.\u00a0 Blood Pressure 5:25-31, 1996.<\/li>\n<\/ol>\n<ol>\n<li value=\"177\">Amerena J, Julius S:\u00a0 The role of the sympathetic nervous system in hypertension.\u00a0 Cardiol Rev 4(6):340-352, 1996.<\/li>\n<\/ol>\n<ol>\n<li value=\"178\">Julius S, Nesbitt S:\u00a0 Sympathetic overactivity in hypertension.\u00a0 A moving target.\u00a0 Am J Hypertens 9:113S-120S, 1996.<\/li>\n<\/ol>\n<ol>\n<li value=\"179\">Palatini P, Julius S:\u00a0 Heart rate and the cardiovascular risk.\u00a0 J Hypertens 15:1-15, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"180\">Vriz O, Nesbitt S, Krause L, Majahalme S, Lu H, Julius S:\u00a0 Smoking is associated with higher cardiovascular risk in young women than in men: the Tecumseh Blood Pressure Study.\u00a0 J Hypertens 15:127-134, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"181\">Julius S:\u00a0 Coronary disease in hypertension: a new mosaic.\u00a0 J Hypertens 15(suppl 2):S3-S10, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"182\">Amerena J, Julius S:\u00a0 Sympathetic overactivity and coronary risk in hypertension.\u00a0 Fundam Clin Pharmacol 11(suppl 1):78s-81s, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"183\">Amerena J, Nesbitt S, Krause L, Grant E, Lu H, Julius S:\u00a0 Trends in left ventricular function over three years in the Tecumseh study.\u00a0 Blood Pressure 6:262-268, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"184\">Palatini P, Julius S:\u00a0 Association of tachycardia with morbidity and mortality: pathophysiological considerations.\u00a0 J Human Hypertens 11(suppl 1):S19-S27, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"185\">Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.\u00a0 The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods.\u00a0 The LIFE Study Group.\u00a0 Am J Hypertens 10(7 Part 1):705-713, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"186\">Julius S, Valentini M: \u00a0Continuing on J.P. Henry\u2019s path; studies of physiology and pathophysiology of cardiopulmonary receptors in humans.\u00a0 Acta Physiol Scand 161(suppl 640):122-124, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"187\">Nesbitt SD, Amerena JV, Grant E, Jamerson KA, Lu H, Weder A, Julius S:\u00a0 Home blood pressure as a predictor of future blood pressure stability in borderline hypertension.\u00a0 The Tecumseh Study.\u00a0 Am J Hypertens 10:1270-1280, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"188\">Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S:\u00a0 Relationship of tachycardia with high blood pressure and metabolic abnormalities.\u00a0 A study with mixture analysis in three populations.\u00a0 Hypertension 30:1267-1273, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"189\">Julius S:\u00a0 Current trends in the treatment of hypertension: A mixed picture.\u00a0 Am J Hypertens 10:300S-305S, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"190\">Palatini P, Julius S, Collatina S, Rappelli S, Staessen, Pessina AC on behalf of the HAROLD study investigators:\u00a0 Optimizing the assessment of the elderly patient with borderline hypertension:\u00a0 the Hypertension and Ambulatory Recording in the OLD (HAROLD) study.\u00a0 Aging Clin Exp Res 9:365-371, 1997.<\/li>\n<\/ol>\n<ol>\n<li value=\"191\">Julius S, Palatini P, Nesbitt S:\u00a0 Tachycardia: an important determinant of coronary risk in hypertension.\u00a0 J Hypertens 16:S9-S15, 1998.<\/li>\n<\/ol>\n<p>&nbsp;<\/p>\n<ol>\n<li value=\"192\">Neel JV, Julius S, Weder A, Yamada M, Kardia SLR, Haviland MB:\u00a0 Syndrome X:\u00a0 is it for real?\u00a0 Gen Epidem 15:19-31, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"193\">Thijs L, Staessen JA, Celis H, de Gaudemaris R, Imai Y, Julius S, Fagard R:\u00a0 Reference values for self-recorded blood pressure: a meta-analysis of summary data.\u00a0 Arch Intern Med 158:481-488, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"194\">Julius S, Nesbitt S:\u00a0 Clinical consequences of the autonomic imbalance in hypertension and congestive heart failure.\u00a0 Scand Cardiovasc J 32:23-30, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"195\">Kjeldsen SE, Hedner T, Jamerson K, Julius S, Haley WE, Zabalgoitia M, Butt AR, Rahman SN, Hansson L, for the HOT Study Group:\u00a0 Hypertension Optimal Treatment (HOT) study.\u00a0 Home blood pressure in treated hypertensive subjects.\u00a0 Hypertension 31:1014-1020, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"196\">Hansson L, Zanchetti A, Carruthers SG, Dahl\u00f6ff B, Elmfeldt D, Julius S, M\u00e9nard J, Rahn KH, Wedel H, Westerling S for the HOT Study Group:\u00a0 Effects of intensive blood-pressure lowering and acetylsalicylic acid in patients with hypertension:\u00a0 principal results of the Hypertension Optimal Treatment (HOT) randomised trial.\u00a0 Lancet 351:1755-1762, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"197\">Julius S:\u00a0 Effect of sympathetic overactivity on cardiovascular prognosis in hypertension.\u00a0 Eur Heart J 19:F14-F18, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"198\">Mann J, Julius S for the VALUE Trial Group:\u00a0 The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension.\u00a0 Rationale and design.\u00a0 Blood Pressure 7:176-183, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"199\">Young EA, Nesse RM, Weder A, Julius S:\u00a0 Anxiety and cardiovascular reactivity in the Tecumseh population.\u00a0 J Hypertens 16:1727-1733, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"200\">Weber MA, Julius S (Editorial):\u00a0 The challenge of very mild hypertension.\u00a0 Should treatment be sooner or later?\u00a0 Am J Hypertens 11:1495-1496, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"201\">Dahl\u00f6ff B, Devereux, RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group:\u00a0 Characteristics of 9194 patients with left ventricular hypertrophy.\u00a0 The LIFE study.\u00a0 Hypertension 32:989-997, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"202\">Neel JV, Weder AB, Julius S:\u00a0 Type II diabetes, essential hypertension, and obesity as \u201csyndromes of impaired genetic homeostasis\u201d: the \u201cthrifty genotype\u201d hypothesis enters the 21st century.\u00a0 Persp Biol Med 42:44-74, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"203\">Julius S, Valentini M: Consequences of the increased autonomic nervous drive in hypertension, heart failure and diabetes.\u00a0 Blood Pressure. Suppl 3:5-13, 1998.<\/li>\n<\/ol>\n<ol>\n<li value=\"204\">Palatini P, Julius S:\u00a0 The physiological determinants and risk correlations of elevated heart rate.\u00a0 Am J Hypertens 12(1, part 2):3S-8S, 1999.<\/li>\n<\/ol>\n<ol>\n<li value=\"205\">Palatini P, Casiglia E, Julius S, Pessina AC:\u00a0 High heart rate.\u00a0 A risk factor for cardiovascular death in elderly men.\u00a0 Arch Intern Med 159:585-592, 1999.<\/li>\n<\/ol>\n<ol>\n<li value=\"206\">Palatini P, Julius S:\u00a0 Relevance of heart rate as a risk factor in hypertension.\u00a0 Curr Hypertens Rpts 3:219-224, 1999.<\/li>\n<\/ol>\n<ol>\n<li value=\"207\">Palatini P, Vriz O, Nesbitt S, Amerena J, Majahalme S, Valentini M, Julius S:\u00a0 Parental hyperdynamic circulation predicts insulin resistance in offspring.\u00a0 The Tecumseh study.\u00a0 Hypertension 33:769-774, 1999.<\/li>\n<\/ol>\n<ol>\n<li value=\"208\">Julius S:\u00a0 Borderline hypertension.\u00a0 Clin and Exper Hypertension 21(5&amp;6):741-747, 1999.<\/li>\n<\/ol>\n<ol>\n<li value=\"209\">Julius S:\u00a0 Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension:\u00a0 The VALUE trial.\u00a0 Cardiology 91(suppl 1):8-13, 1999.<\/li>\n<\/ol>\n<ol>\n<li value=\"210\">Thijs L, Staessen JA, Celis H, Fagard R, De Cort P, de Gaudemaris R, Enstr\u00f6m I, Imai Y, Julius S, M\u00e9nard J, Mion D, Palatini P, Rosenfeld J, Shapiro D, Spence D, Stergiou G:\u00a0 The international database of self-recorded blood pressures in normotensive and untreated hypertensive subjects.\u00a0 Blood Pressure Monitoring 4:77-86, 1999.<\/li>\n<\/ol>\n<ol>\n<li value=\"211\">Julius S, Brunner H:\u00a0 Challenging the paradigm for treatment of hypertension: focus on elevated systolic blood pressure \u2013 Introduction.\u00a0 Am Heart J 138(3):S203-S204, 1999.<\/li>\n<\/ol>\n<ol>\n<li value=\"212\">Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Hoieggen A, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S:\u00a0 Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension.\u00a0 ICARUS, a LIFE substudy.\u00a0 J Hypertens 18:75-81, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"213\">Julius S:\u00a0 Trials of antihypertensive treatment &#8211; new agenda for the millennium.\u00a0 Am J Hypertens 13:11S-17S, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"214\">Julius S, Valentini M, Palatini P:\u00a0 Overweight and hypertension.\u00a0 A 2-way street?\u00a0 Hypertension 35:807-813, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"215\">Yarows SA, Julius S, Pickering TG:\u00a0 Home blood pressure monitoring.\u00a0 Arch Intern Med 160:1251-1257, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"216\">Julius S:\u00a0 Worldwide trends and shortcomings in the treatment of hypertension.\u00a0 Am J Hypertens 13(5, part 2):57S-61S, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"217\">Nesbitt S, Julius, S:\u00a0 Prehypertension: A possible target for antihypertensive medication.\u00a0 Curr Hypertens Rpts 2:356-361, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"218\">Palatini P, Majahalme S, Amerena J, Nesbitt S, Vriz O, Michieletto M, Krause L, Julius S:\u00a0 Determinants of left ventricular structure and mass in young subjects with sympathetic over-activity.\u00a0 The Tecumseh offspring study.\u00a0 J Hypertens 18:769-775, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"219\">Brook RD, Julius S:\u00a0 Autonomic imbalance, hypertension, and cardiovascular risk.\u00a0 Am J Hypertens 13(6, part 2):112S-122S, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"220\">Julius S:\u00a0 Five decades of antihypertensive treatment: the unresolved issues.\u00a0 J Hypertens 18(Suppl 3):S3-S7, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"221\">Kjeldsen SE, Dahloff B, Devereux RB, Julius S, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen, O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel, for the LIFE study group:\u00a0 Lowering of blood pressure and predicators of response in patients with left ventricular hypertrophy: the LIFE study.\u00a0 Am J Hypertens 13:899-906, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"222\">Julius S, Majahalme S:\u00a0 The changing face of sympathetic overactivity in hypertension.\u00a0 Ann Med 32:365-370, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"223\">Okin PM, Devereux, RB, Jern S, Kjeldsen SE, Julius S, Dahloff B for the LIFE Study Investigators:\u00a0 Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients.\u00a0 The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study.\u00a0 Hypertension 36:766-773, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"224\">Julius S: New Clinical Trials of Angiotensin Blockade in Cardiovascular Disease: Foreward.\u00a0 Am J Hypertens 13(5, part 2):55S, 2000.<\/li>\n<\/ol>\n<ol>\n<li value=\"225\">Kjeldsen SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, Laragh J, McInnes G, Smith B, Weber M, Zanchetti A for the VALUE Trial Group:\u00a0 Characteristics of 15314 hypertensive patients at high coronary risk.\u00a0 The VALUE Trial.\u00a0 Blood Pressure 10:83-91, 2001.<\/li>\n<\/ol>\n<ol>\n<li value=\"226\">Palatini P, Krause L, Amerena J, Nesbitt S, Majahalme S, Tikhonoff V, Valentini M, Julius S:\u00a0 Genetic contribution to the variance in left ventricular mass: the Tecumseh Offspring Study.\u00a0 J Hypertens 19:1217-1222, 2001.<\/li>\n<\/ol>\n<ol>\n<li value=\"227\">Okin PM, Devereux RB, Jern S, Julius S, Kjeldsen SE, Dahlof B, for the LIFE Study Investigators:\u00a0 Relation of echocardiographic left ventricular mass and hypertrophy to persistent electrocardiographic left ventricular hypertrophy in hypertensive patients: the LIFE study.\u00a0 Am J Hypertens 14:775-782, 2001.<\/li>\n<\/ol>\n<ol>\n<li value=\"228\">Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Dahl\u00f6f B, for the LIFE Study Investigators:\u00a0 Relationship of electrocardiographic strain pattern to left ventricular structure and function in hypertensive patients: the LIFE study.\u00a0 JACC 38:412-520, 2001.<\/li>\n<\/ol>\n<ol>\n<li value=\"229\">Julius S, Majahalme S, Palatini P:\u00a0 Antihypertensive treatment of patients with diabetes and hypertension.\u00a0 Am J Hypertens 14:310S-316S, 2001.<\/li>\n<\/ol>\n<ol>\n<li value=\"230\">Reims H, Fossum E, Kjeldsen SE, Julius S:\u00a0 Home blood pressure monitoring.\u00a0 Current knowledge and directions for future research.\u00a0 Blood Pressure 10:271-287, 2001.<\/li>\n<\/ol>\n<ol>\n<li value=\"231\">Kjeldsen SE, Julius S, Hedner T, Hansson L: Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials.\u00a0 Blood Pressure 10:190-192, 2001<\/li>\n<\/ol>\n<ol>\n<li value=\"232\">Julius S:\u00a0 The association of tachycardia with obesity and elevated blood pressure.\u00a0 J Pediatr. 140(6):643-5, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"233\">Parati G, de Leeuw P, Illyes M, Julius S, Kuwajima I, Mallion JM, Ohtsuka K, Imai Y, Blood pressure measurement in research. Blood Pressure Monitoring. 7(1):83-87, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"234\">Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, \u00a0de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE study group:\u00a0 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol.\u00a0 Lancet 359:995-1003, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"235\">Lindholm LH, Ibsen H, Dahl\u00f6f B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, for the LIFE study group:\u00a0 Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.\u00a0 Lancet 359: 1004-10, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"236\">Julius S, Majahalme S, Nesbitt, Grant E, Kaciroti N, Ombao H, Vriz, Valentini M, Amerena J and Gleiberman L:\u00a0 A \u201cgender blind\u201d relationship of lean body mass and blood pressure in the Tecumseh, study.\u00a0 Am J Hypertens 15:258-263, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"237\">Okin PM, Wright JT, Nieminen MS, Julius S, Devereux RB for LIFE Study Investigators, et al: Ethnic Differences in Electrocardiographic Criteria for Left Ventricular Hypertrophy:\u00a0 The LIFE Study.\u00a0 Am J Hypertens;15,663-71, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"238\">Palatini P, Amerena J, Nesbitt S, Valentini M, \u00a0Majahalme S, Krause L, Tikhonoff V and \u00a0Julius S: Heritability of left atrial size in the Tecumseh population. European Journal of Clinical Investigation 32(7):467\u2013471, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"239\">Skov K, Julius S, Nesbitt S, Mulvany MJ: Can hypertension be prevented? The Danish Hypertension Prevention Project and the Trial of Prevention of Hypertension studies. Current Opinion in Cardiology;17:380\u2013384, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"240\">Kjeldsen SE, Dahlof B, Devereux RB, Julius S, et al:\u00a0 Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients with Isolated Systolic Hypertension and Left Ventricular Hypertrophy.\u00a0 JAMA 288(12):1491-8, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"241\">Palatini P, Julius S:\u00a0 Pathophysiology of the Association between Increased Heart Rate and Cardiovascular Morbidity and Mortality.\u00a0 Medicographia; 24(3):201-6, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"242\">Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, Devereux RB, Julius S, Kjeldsen SE, etal. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens;20(9);1879-86, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"243\">Zanchetti A, Hansson L, Dahl\u00f6f B, Julius S, M\u00e9nard J; Warnold I, Wedel H, on behalf of the HOT Study Group: \u00a0Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk J Hypertens 20(11): 2301-2307, 2002.<\/li>\n<\/ol>\n<ol>\n<li value=\"244\">Julius S: Lennart Hansson, MD &#8211; In memoriam. Hypertension. 41(1):1-2, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"245\">Julius S: The ALLHAT study: if you believe in evidence-based medicine, stick to it! J Hypertens. 21(3):453-454, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"246\">Julius S: Bringing VALUE to LIFE. European Heart Journal Supplements. 5(C):C5-C8, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"247\">Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, Waeber B, Wedel H: HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers?\u00a0 J Hypertens. 21(4):797-804, 2003.<\/li>\n<li value=\"248\">Julius S: \u00a0Of rat and man.\u00a0 J Hypertens 21(4):705-6, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"249\">Olsen MH, Hjerkinn E, Wachtell K, Hoieggen A, Bella JN, Nesbitt SD, Fossum E, Kjeldsen SE, Julius S, Ibsen H:\u00a0 Are left ventricular mass, geometry and function related to vascular changes and\/or insulin resistance in long-standing hypertension? ICARUS: a LIFE substudy.\u00a0 J Human Hypertension. 17(5):305-11, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"250\">Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, Laragh JH, McInnis G, Schork AM, Smith B, Weber M, Zanchetti A:\u00a0 VALUE Trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk.\u00a0 Am J Hypertens 16(7):544-8, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"251\">Devereux RB, Dahlof B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, Helle Berg S, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H:\u00a0 LIFE Study Group. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.\u00a0 Ann Int Med. 139(3):169-77, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"252\">Okin PB, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B:\u00a0 Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.\u00a0 Circulation. 108(6):684-90, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"253\">Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P:\u00a0 Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.\u00a0 Ann Int Med. 139(11):901-6, 2003.<\/li>\n<\/ol>\n<ol>\n<li value=\"254\">Julius S, Cohn JN, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Lagast H:\u00a0 Antihypertensive utility of perindopril in a large, general practice-based clinical trial.\u00a0 J Clinical Hypertens (Greenwich) 6(1):10-17, January, 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"255\">Cohn JN, Julius S, Neutel J, Weber M, Turlapaty P, Shen Y, Dong V, Batchelor A, Guo W, Lagast H:\u00a0 Clinical experience with perindopril in African-American hypertensive patients: a large United States community trial. Am J Hypertens. 17(2):134-8, Feb. 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"256\">Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS:\u00a0 Omvik P. Oparil S. Wedel H. Chen C. Dahlof B; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study.\u00a0 Kidney Int. 65(3):1041-1049, March 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"257\">Julius S, Alderman MH, Beevers G, Dahl\u00f6f B, Devereux RB, Douglas JG, Edelman JM, Harris KE, Kjeldsen SE, Nesbitt S, Randall OS, Wright, Jr. JT: \u00a0Cardiovascular Risk Reduction in Hypertensive Black Patients with Left Ventricular Hypertrophy.\u00a0 JACC. 43(6):1047-1055, March 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"258\">Fossum E, Olsen MH, H\u00f8ieggen A, Wachtell K, Reims HM, Ibsen H, Julius S, Kjeldsen SE: Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.\u00a0 J Human Hypertens. 18:375-380, June 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"259\">Reims HM, Kjeldsen SE, Brady WE, Dahl\u00f6f B, Devereaux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pederson O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H for the LIFE study group: Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.\u00a0 J Human Hypertens, Special LIFE issue. 18:381-389, April 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"260\">Okin PM, Devereaux RB, Liu JE, Oikarinen L, Jern S, Kjeldsen SE, Julius S, Wachtell K, Nieminen MS, Dahl\u00f6f: Regression of electrocardiographic left ventricular hypertrophy predicts regression of echocardiographic left ventricular mass: the LIFE study. J Human Hypertens. 18:403-409, April 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"261\">Julius S, Kjeldsen, SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A, for the VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial.\u00a0 Lancet. 363:2022-31, June 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"262\">Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Shork MA, Smith B, Zanchetti A: Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.\u00a0 Lancet. 363:2049-51, June 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"263\">Okin PM, Devereux RB, Nieminen MS, Jern S, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Julius S, Snapinn S, Dahlof B, for the LIFE Study Investigators: Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients.\u00a0 Hypertension. 44:48-54, July 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"264\">Julius S, Nesbitt S, Egan B, Kaciroti N, Schork MA, Grozinski M, Michelson E, for the TROPHY study group: Trial of preventing hypertension, Design and 2-year progress report.\u00a0 Hypertension. 44:146-151, August 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"265\">Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Morgensen CE, Dahl\u00f6f B, Devereaux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y: Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.\u00a0 J Hypertens. 22:1805-1811, Sept. 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"266\">Valentini M, Julius S, Palatini P, Brook RD, Bard RL, Bisognano JD, Kaciroti N: Attenuation of\u00a0 haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens. 22:1999-2006, July 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"267\">Neutel JM, Weber MA, Julius S, Cohn JN, Turlapaty P, Shen Y, Guo W, Batchelor A, Lagast H: Clinical experience with perindopril in elderly hypertensive patients.\u00a0 A subgroup analysis of a large community trial.\u00a0 Am J Cardiovasc Drugs. 4 (5):335-341, July 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"268\">H\u00f8eggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, Fyhrquist J, Ibsen H, Kristianson K, Lederball-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Chen C, Dahl\u00f6f B, for the LIFE study group: The impact of serum uric acid on cardiovascular outcomes in the LIFE study.\u00a0 Kidney International. 65:1041-1049, September 2004.<\/li>\n<\/ol>\n<ol>\n<li value=\"269\">Kjeldsen SE, Julius S: Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.\u00a0 Am Heart. 148:747-54, November 2004.<\/li>\n<li value=\"270\">Egan BM, Julius S: Role of sympathetic overactivity in the pathophysiology of the metabolic syndrome.\u00a0 Dialogues Cardiovasc Med. 9:143-157, November 2004.<\/li>\n<li value=\"271\">Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, Fyhrquist F, Ibsen H, Lindholm LH, Omvik P, Wedel H, Beevers G, de Faire U, Kristianson K, Lederballe-Pederson O, Nieminen M, Dahl\u00f6f B, for the LIFE Study Group: Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.\u00a0 Blood Pressure. 13:376-384, November 2004.<\/li>\n<li value=\"272\">Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahl\u00f6f B, for the LIFE Study Investigators: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 292:2343-2349, November 2004.<\/li>\n<li value=\"273\">Palatini P, Julius S: Elevated heart rate: a major risk factor for cardiovascular disease.\u00a0 Clinical &amp; Experimental Hypertension. 26(7-8):637-44 November 2004.<\/li>\n<li value=\"274\">Kizer JR, Dahl\u00f6f B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB: Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus\u00a0 atenolol.\u00a0 The losartan intervention for endpoint reduction in hypertension study. Hypertension. 45:46-52, January 2005.<\/li>\n<li value=\"275\">Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Morgensen CK, Dahl\u00f6f B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pederson O, Nieminen MS, Omvik P, Oparil S, Wan Y: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients.\u00a0 Losartan intervention for endpoint reduction in hypertension study.\u00a0 Hypertension. 45:198-202, February 2005.<\/li>\n<li value=\"276\">Egan BM, Papademetriou V, Wofford M, Calhoun D, Fernandes J, Riehle JE, Nesbitt S, Michelson E, Julius S, for the TROPHY sub-study investigative team:\u00a0 Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure.\u00a0 Am J Hypertens. 18: 3-12, January 2005.<\/li>\n<li value=\"277\">Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahl\u00f6f B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB: Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation.\u00a0 The losartan intervention for end point reduction in hypertension (LIFE) study.\u00a0 J Am Coll Cardiol. 45:705-11, March 2005.<\/li>\n<li value=\"278\">Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahl\u00f6f B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol.\u00a0 The losartan intervention for end point reduction in hypertension (LIFE) study.\u00a0 J Am Coll Cardiol. 45:712-9, March 2005.<\/li>\n<li value=\"279\">Kjeldsen SE, Lyle PA, Kiser JR, Dahl\u00f6f B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H, for the LIFE Study Group: The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy.\u00a0 J Clinical Hypertension. 7:152-158, March, 2005.<\/li>\n<li value=\"280\">Fyhrquist F, Dahl\u00f6f B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; for the LIFE Study Group:\u00a0 Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.\u00a0 Hypertens. 45:580-585, April 2005.<\/li>\n<li value=\"281\">Olsen MH, Fossum E, H\u00f8eiggen A, Wachtell K, Hjerkinn E, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S: Long term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy.\u00a0 J of Hypertens. 23:891-898, April 2005.<\/li>\n<li value=\"282\">de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahl\u00f6f B, de Faire U, Fyhrquist F,\u00a0 Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB: Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy.\u00a0 The LIFE (Losartan intervention for endpoint reduction in hypertension) study.\u00a0 Circulation. 111:1924-1931, April 2005.<\/li>\n<li value=\"283\">Nesbitt SD, Julius S, Leonard D, Egan BM, Grozinski M, for the TROPHY Study Investigators: Is low-risk hypertension fact or fiction?\u00a0 Am J Hypertens. 18:980-985, July 2005.<\/li>\n<li value=\"284\">Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahl\u00f6f B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y:\u00a0 Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients.\u00a0 Hypertension 45:198-202, 2005.<\/li>\n<li value=\"285\">Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahl\u00f6f B, for the LIFE Study Group: The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin.\u00a0 J Am Coll Cardiol 46:770-5, Sept. 2005.<\/li>\n<li value=\"286\">Palatini P, Benetos A, Julius S: Impact of increased heart rate on clinical outcomes in hypertension.\u00a0 Drugs 66(2):133-144, 2006.<\/li>\n<li value=\"287\">Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA for the Trial of Preventing Hypertension (TROPHY) Study Investigators:\u00a0 Feasibility of treating prehypertension with an angiotensin-receptor blocker.\u00a0 N Engl J Med 354:1685-97, April 2006.<\/li>\n<li value=\"288\">Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahl\u00f6f B, for the LIFE Study Investigators: Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy.\u00a0 The Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.\u00a0 Circulation 113:1588-96, March 2006.<\/li>\n<li value=\"289\">Fossum E, Olsen MH, H\u00f8ieggen A, Wachtell K, Reims HM, Kjeldsen SE, Ibsen H, Wan Y, Julius S:\u00a0 Long-term effects of a losartan-compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.\u00a0 J Clin Hypertens 8:169-173, April 2006.<\/li>\n<li value=\"290\">Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A:\u00a0 Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting.\u00a0 J Hypertens 24:603-610, April 2006.<\/li>\n<li value=\"291\">Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA, Coca A, Ekman S, Girerd X, Jamerson K, Larochelle P, MacDonald TM, Schmeider RE, Schork MA, Stolt P, Viskoper R, Widimsky J, Zanchetti A; for the VALUE Trial Investigators.\u00a0 Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.\u00a0 J Hypertens 24(7):1405-1412, July 2006.<\/li>\n<li value=\"292\">Kjeldsen SE, Strand A, Julius S, Okin PM.\u00a0 Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy.\u00a0 J Clin Hypertens 8:487\u2011492, July 2006.<\/li>\n<li value=\"293\">Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjech I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martinez F, Oigman W, Seabra Gomes R, Zhu JR.\u00a0 The valsartan antihypertensive long-term use evaluation (VALUE) trial.\u00a0 Outcomes in patients receiving monotherapy.\u00a0 Hypertens 48:385-391, March 2006.<\/li>\n<li value=\"294\">Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, Nieminen MS, Edelman JM, Hille DA, Dahl\u00f6f B.\u00a0 Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 296:1242-1248, September 2006.<\/li>\n<li value=\"295\">Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, Laragh JH, Plat F, Battegay E, Calvo-Vargas C, Cieslinski A, Degaute JP, Holwerda NJ, Kobalava J, Pedersen OL, Rudyatmoko FP, Siamopoulos KC, Storset O:\u00a0 Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial.\u00a0 J Hypertens 24(11):2163-2168, 2006<\/li>\n<li value=\"296\">Pedersen OL, Mancia G, Pickering T, Hoegholm A, Julius S, Kjeldsen SE, Nielsen ES, Refsgaard J, Weber M, for the VALUE trial group: Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. J Hypertens 25(3):707-712, 2007.<\/li>\n<li value=\"297\">Mancia G, Bousquet P, Elghozi JL, Esler M. Grassi G, Julius S, Reid J, Van Zwieten PA: The sympathetic nervous system and the metabolic syndrome. J Hypertens 25:909-920, 2007.<\/li>\n<li value=\"298\">Julius S. Should the results of TROPHY affect the JNC definition of prehypertension?\u00a0 Current Hypertension Reports, 9:202-205, 2007.<\/li>\n<li value=\"299\">Fossum E, Gleim GW, Kjeldsen SE, Kizer JR, Julius S, Devereux RB, Brady WE, Hille DA, Lyle PA, Dahl\u00f6f B.\u00a0 The effect of baseline physical activity on cardiovascular outcomes and new-onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study. \u00a0J Internal Medicine, 262(4):439-448, 2007.<\/li>\n<li value=\"300\">Ruilope LM, Zanchetti A, Julius S, McInnes GT, Segura J, Stolt P, Hua TA, Weger MA, Jamerson K, for the VALUE Investigators.\u00a0 Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial.\u00a0 J Hypertens, 25:1473-1479, 2007.<\/li>\n<li value=\"301\">Julius S. Blood pressure lowering only or more?\u00a0 Has the jury reached its verdict?\u00a0 Am J Cardiol, 100[suppl]:32J-37J, 2007.<\/li>\n<li value=\"302\">Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the valsartan antihypertensive long-term use evaluation (VALUE) trial population. \u00a0Hypertension, 50:467-473, 2007.<\/li>\n<li value=\"303\">Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahl\u00f6f B, for the LIFE Study Investigators.\u00a0 Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Ann Intern Med.\u00a0 147:311-319, 2007.<\/li>\n<li value=\"304\">Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL for the Trial of Preventing Hypertension (TROPHY) Investigators.\u00a0 TROPHY Study: Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension.\u00a0 Journal of the American Society of Hypertension 2(1):39-43, 2008.<\/li>\n<li value=\"305\">Okin PM, Wachtell K, Devereux RB, Nieminen MS, Oikarinen L, Vitasalo M, Toivonen L, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Kjeldsen SE, Julius S, and Dahl\u00f6f B, for the LIFE Study Investigators.\u00a0 Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: The LIFE Study. Am J Hypertens 21:273-279, 2008.<\/li>\n<li value=\"306\">Aksnes TA, Schmieder, RE, Kjeldsen SE, Ghani S, Hua TA, Julius S.\u00a0 Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high risk hypertension (from the VALUE trial). Am J Cardiol 101:634-638, 2008.<\/li>\n<li value=\"307\">Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, for the VALUE trial group.\u00a0 Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.\u00a0 J Hypertens 26:403-411, 2008.<\/li>\n<li value=\"308\">Oparil S, Abate N, Chen E. Creager MA, Galet V, Jia G, Julius S, Lerman A, Lyle PA, Pool J, Tershakovec AM. A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.\u00a0 Current Medical Research and Opinion 24(4):1101-1114, 2008.<\/li>\n<li value=\"309\">Okin PM, Gerdts E, Kjeldsen SE, Julius S, Edelman JM, Dahl\u00f6f B, Devereux RB, for the Losartan Intervention for Endpoint Reduction in Hypertension Study Investigators.\u00a0 Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy.\u00a0 Hypertension 52:1-7, 2008.<\/li>\n<li value=\"310\">Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S, for the TROPHY Study Investigators.\u00a0 An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY). J Clin Hypertens, 10:436-442, 2008.<\/li>\n<li value=\"311\">Aksnes TA, Rostrup M,\u00a0<u>Kjeldsen SE<\/u>, St\u00f6rset \u00d8, Hua A, Julius S. Predictors of new-onset diabetes mellitus in high risk hypertensive patients in the Value Trial. J Hum Hypertens\u00a0 22(8):520-7, 2008.<\/li>\n<li value=\"312\">Messerli FH, Bangalore S, Julius S. \u00a0Risk\/benefit assessment of \u03b2-blocker and diuretics precludes their use for first line therapy in hypertension. Circulation 117:2706-2715, 2008.<\/li>\n<li value=\"313\">Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Schork MA, Viskoper R, Widimsky J, Zanchetti A. for the VALUE Trial Investigators.\u00a0 Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial.\u00a0 Blood Pressure 17:170-177, 2008.<\/li>\n<li value=\"314\">Egan BM, Nesbitt SD, Julius S. Prehypertension: should we be treating with pharmacologic therapy?\u00a0 Therapeutic Advances in Cardiovascular Disease, 2(4), 305-314, 2008.<\/li>\n<li value=\"315\">Egan BM, Julius S.\u00a0 Prehypertension: risk stratification and management considerations.\u00a0 Current Hypertension Reports, 10:359-366, 2008.<\/li>\n<li value=\"316\">Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahl\u00f6f B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.\u00a0 Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE Study.\u00a0 Circ Arrhythmia Electrophysiol 1;337-343, 2008.<\/li>\n<li value=\"317\">Aksnes TA, Tjugen TB, Schmieder RE, Kjeldsen SE, Julius S.\u00a0 Impact of diabetes development on atrial fibrillation in hypertensive patients. \u00a0Cardiology Review 25:44-47, 2008.<\/li>\n<li value=\"318\">Sasamura H, Nakaya H, Julius S, Takebayashi T, Sato Y, Uno H, Takeuchi M, Ishiguro K, Murakami M, Ryuzaki M, Itoh H, STAR CAST Investigators.\u00a0 The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design.\u00a0 Hypertension Research \u2013 Clinical &amp; Experimental. 31(10):1843-9, 2008.<\/li>\n<li value=\"319\">Palatini P, Parati G, Julius S.\u00a0 Office and out of office heart rate measurements: which clinical value?\u00a0 J Hypertens 26:1540-1545, 2008.<\/li>\n<li value=\"320\">Kaciroti NA, Schork MA, Raghunathan T, Julius S.\u00a0 A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropouts. \u00a0Statist. Med. 28:572-585, 2009.<\/li>\n<li value=\"321\">Julius S. Prehypertension in China.\u00a0 J Hypertens 27:700-701, 2009.<\/li>\n<li value=\"322\">Palatini P, Julius S. The role of cardiac autonomic function in hypertension and cardiovascular disease.\u00a0 Current Hypertension Reports 11:199-205, 2009.<\/li>\n<li value=\"323\">Julius S. Tachycardia in hypertension; a saga of progress despite prejudice, confusion and inertia.\u00a0 Prog Cardiovasc Dis 52:26-30, 2009.<\/li>\n<li value=\"324\">Aksnes TA, Kjeldsen SE, Julius S.\u00a0 Atrial fibrillation and hypertension. Arch Med Sci 5, 2A:S 267-272, 2009.<\/li>\n<li value=\"325\">Feldstein C, Julius S. The complex interaction between overweight, hypertension and sympathetic overactivity.\u00a0 JASH 3;6:353-365, 2009.<\/li>\n<li value=\"326\">Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahl\u00f6f B, Julius S, Edelman JM, Snapinn SM, De Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.\u00a0 Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study. Blood Pressure, 18;6:348-361, 2009.<\/li>\n<li value=\"327\">Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahl\u00f6f B, Edelman JM, Devereux RB.\u00a0 All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy.\u00a0\u00a0<a title=\"European heart journal.\">Eur Heart J.<\/a>\u00a0\u00a031:2271-2279, 2010.<\/li>\n<li value=\"328\">Feldstein C, Julius S. Establishing targets for hypertension control in patients with comorbidities.\u00a0 Curr Hypertens Rep 12:465-473, 2010.<\/li>\n<li value=\"329\">Julius S, Kjeldsen SE, Weber MA. Angiotensin-receptor blockade, cancer and concerns. Lancet Oncology 1(9):820-1, 2010.<\/li>\n<li value=\"330\">The ARB Trialists Collaboration.\u00a0 Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.\u00a0 Journal of Hypertension 29:623-635, 2011.<\/li>\n<li value=\"331\">Pitt B, Julius S.\u00a0\u00a0<a title=\"Complete Reference\" href=\"http:\/\/ovidsp.tx.ovid.com\/sp-3.4.2a\/ovidweb.cgi?&amp;S=FNBGFPFGJLDDKOONNCALOBGCLHFIAA00&amp;Complete+Reference=S.sh.19%7c1%7c1\">Easy money? Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class.<\/a>\u00a0International Journal of Clinical Practice 65(3):242-4, 2011.<\/li>\n<li value=\"332\">Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahl\u00f6f B, Devereux RB.\u00a0 Effect of changing heart rate during treatment of hypertension on incidence of heart failure.\u00a0 Am J Cardiol \u00a0Mar 1;109(5):699-704, 2012. Epub 2011 Dec 10.<\/li>\n<li value=\"333\">Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N.\u00a0 Usefulness of Heart rate to predict cardiac events in treated patients with high risk systemic hypertension.\u00a0 Am J Cardiol 109:685-692, 2012.<\/li>\n<li value=\"334\">Kaciroti NA, Raghunathan TE, Taylor JMG, Julius S.\u00a0 A Bayesian model for time-to-event data with informative censoring.\u00a0 Biostatistics (in print 2012).<\/li>\n<li value=\"335\">Okin PM, Kjeldsen SE, Julius S, Dahl\u00f6f B, Devereux RB.\u00a0 Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: The LIFE study.\u00a0 Heart Rhythm, 9(4) 531-537, 2012.<\/li>\n<li value=\"336\">Weber MA, Julius S, Kjeldsen SE, Jia Y, Brunner HR, Zappe DH,. Hua TA, McInnes GT, Schork A, Mancia G, Zanchetti A.\u00a0 Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. Journal of Hypertension. \u00a030:2213-2222, 2012.<\/li>\n<li value=\"337\">Levitan EB, Kaciroti N, Oparil S, Julius S, Muntner P.\u00a0 Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure.\u00a0 J Clin Hypertens (Greenwich). 14:744-750, 2012.<\/li>\n<li value=\"338\">Julius S, Kaciroti N, Oparil S. Reply to visit-to-visit blood pressure variation: time to reanalyze all the data from the TROPHY study.\u00a0 Journal of Clinical Hypertension 15(4):301, 2013.<\/li>\n<li value=\"339\">Levitan, EB, Kaciroti N, Oparil S, Julius S, Muntner P. Relationships between metrics of visit-to-visit variability of blood pressure.\u00a0 Journal of Human Hypertension 2013 Oct;27(10):589-93.<\/li>\n<li value=\"340\">Sasamura H, Nakaya H, Julius S, Tomotsugu N, Sato Y, Takahashi F, Takeuchi M, Murakami M, Ryuzaki M, Itoh H; STAR CAST investigators.\u00a0 Feasibility of regression of hypertension using contemporary antihypertensive agents.\u00a0 Am J Hypertens. 2013 Dec;26(12):1381-8.<\/li>\n<li value=\"341\">Julius S, Egan BM, Kaciroti NA, Nesbitt SD, Chen AK. for TROPHY investigators. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension. \u00a0\u00a0J Hypertens. \u00a02014. Feb 32(2):251-9.<\/li>\n<li value=\"342\">Okin PM, Bang CN, Wachtell K, Hille DA, Kjeldsen SE, Julius S, Dahlof B, Devereux RB.\u00a0 Racial differences in incident atrial fibrillation among hypertensive patients during antihypertensive therapy. Am J Hypertens 2014, 27(7):966-72.<\/li>\n<li value=\"343\">Ference BA, Julius S, Mahajan N, Levy PD, Williams KA Sr, Flack JM. Clinical effect of naturally random allocation to lower systolic blood pressure beginning before the development of hypertension.\u00a0 Hypertension. \u00a02014. \u00a063(6):1182-88.<\/li>\n<li value=\"344\">Kjeldsen SE, Julius S, Dahl\u04e7f B, Weber MA.\u00a0 Physician (investigator) inertia in apparent treatment-resistant hypertension \u2013 Insights from large randomized clinical trials.\u00a0 Blood Pressure, 2015. 24(1):1-6.<\/li>\n<li value=\"345\">Sandset EC, Berge E, Kjeldsen SE, Julius S, Holzhauer B, Krarup LH, Hua TA.\u00a0 Heart Rate as a Predictor of Stroke in High-risk, Hypertensive Patients with Previous Stroke or Transient Ischemic Attack.\u00a0 Journal of Stroke and Cerebrovascular Diseases.\u00a0 2014;232(10):2814-18.<\/li>\n<li value=\"346\">Kjeldsen SE, Berge E, Bangalore S, Messerli FH, Mancia G, Holzhauer B, Hua TA, Zappe D, Zanchetti A, Weber MA, Julius S.\u00a0 No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.\u00a0 Blood Pressure. 2016;25(2):83-92.<\/li>\n<li value=\"347\">Aksnes TA, Kjeldsen SE, Rostrup M, Holzhauer B, Hua TA, Julius S. Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The VALUE trial. Blood Pressure 2016; in press.<\/li>\n<li value=\"348\">Palatini P, Rosei EA, Casiglia E, Chalmers J, Ferrari R, Grassi G, Inoue T, Jelakovic B, Jensen MT, Julius S, Kjeldsen SE, Mancia G, Parati G, Pauletto P, Stella A, Zanchetti A.\u00a0 Management of the hypertensive patient with elevated heart rate: statement of the second consensus conference endorsed by the European Society of Hypertension.\u00a0 J Hypertens 2016 Mar 15. Epub ahead of print<\/li>\n<\/ol>\n<p>Books Written and Edited<\/p>\n<p>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Mudrost Tijela (Wisdom of our body) Epoha, Zagreb 1960<\/p>\n<p>Slovenian translation Cankarjeva\u00a0 Zalozba, Ljubljana 1962<\/p>\n<p>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Na Zivcanoj Bazi (On a nervous basis) Epoha Zagreb, 1960<\/p>\n<p>Slovenian translation Cankarjeva\u00a0 Zalozba, Ljubljana 1960<\/p>\n<p>Hungarian translation Forum, Novi Sad 1962<\/p>\n<p>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Esler MD, ed.\u00a0<em>The Nervous System in Arterial Hypertension.<\/em>\u00a0 Springfield, IL Charles C Thomas, 1976<\/p>\n<p>4\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Neither Red Nor Dead\u00a0 Medvista,\u00a0 AnnArbor, 2003<\/p>\n<p>Croatian translation Durieux, Zagreb 2005<\/p>\n<p>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Adventures In Hypertension\u00a0 Medvista,\u00a0 AnnArbor2008<\/p>\n<p>Croatian translation A.G. Matos, Zagreb 2011<\/p>\n<p>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Palatini P.\u00a0 Resting heart rate as a cardiovascular risk factor. CESI srl,\u00a0Rome 2015<\/p>\n<p>&nbsp;<\/p>\n<p align=\"left\">Chapters in Books (Peer-reviewed):<\/p>\n<p>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 &#8220;Effect of autonomic blockade in normal cardiac output type of borderline hypertension&#8221;, in: P Milliez and M Safar (eds.), Recent Advances in Hypertension.\u00a0 Reims, France, Boehringer Ingelheim (2nd ed.), pp. 217-226, 1975.<\/p>\n<p>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Esler M, Julius S, Randall O:\u00a0 \u201cRelationship of volume factors, renin and neurogenic vascular resistance in borderline hypertension\u201d, in: G Rorive and H Van Cauwenberge (eds.), The Arterial Hypertensive Disease \u2013 A Symposium.\u00a0 Paris, P Masson, pp. 231-249, 1976.<\/p>\n<p>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cNeurogenic component in borderline hypertension\u201d in: S Julius and M Esler (eds.), The Nervous System in Arterial Hypertension.\u00a0 Springfield, Illinois, Charles C. Thomas, pp. 301-330, 1976.<\/p>\n<p>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Esler MD, Julius S, Randall O, Kashima T:\u00a0 \u201cRenin and indices of neurogenic activity in borderline hypertension\u201d, in: S Julius and M Esler (eds.), The Nervous System in Arterial Hypertension.\u00a0 Springfield, Illinois, Charles C. Thomas, pp. 331-354, 1976.<\/p>\n<p>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Esler M, Hansson L, Zweifler AJ:\u00a0 \u201cDissociation of the renin lowering and antihypertensive actions of propranolol\u201d, in: G Hitzenberger (volume ed.) Advances in Clinical Pharmacology.\u00a0 Beta-Blocker in der Hypertonie-Behandlung (Vol. 11).\u00a0 Munchen-Wien-Baltimore, Urban and Schwarzenberg, pp. 33-41, 1976.<\/p>\n<p>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cClassification of hypertension\u201d, in: J Genest, E Koiw and O Kuchel (eds.), Hypertension.\u00a0 New York, McGraw-Hill, pp. 9-12, 1977.<\/p>\n<p>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cBorderline hypertension: epidemiological and clinical implications\u201d, in: J Genest, E Koiw and O Kuchel (eds.), Hypertension.\u00a0 New York, McGraw-Hill, pp. 630-640, 1977.<\/p>\n<p>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Esler M:\u00a0 \u201cPatterns of neurogenic involvement in borderline and essential hypertension\u201d, in: W DeJong, AP Provoost and AP Shapiro (eds.), Progress in Brain Research, Hypertension and Brain Mechanisms.\u00a0 Amsterdam, Elsevier Series Vol. 47, pp. 251-262, 1977.<\/p>\n<p>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cBorderline hypertension: significance and management\u201d, in: G Onesti and AN Brest (eds.), Cardiovascular clinics 9\/1, Hypertension: Mechanisms, Diagnosis and Treatment.\u00a0 Philadelphia, FA Davis Co., pp. 31-41, 1978.<\/p>\n<p>10.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S and Schork MA:\u00a0 \u201cPredictors of hypertension\u201d, in: HM Perry, Jr. and WM Smith (eds.), Mild Hypertension: To Treat or Not to Treat .\u00a0 Annals of the New York Academy of Sciences, New York Academy of Sciences Vol. 304, pp. 38-52, 1978.<\/p>\n<p>11.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cBorderline hypertension: clinical and pathophysiologic significance\u201d, in: H von P Frick, G-A von Harnack, GA Martini, A Prader, R Schoen and HP Wolff (eds.), Advances in Internal Medicine and Pediatrics.\u00a0 Heidelberg, Springer-Verlag, Vol. 41, pp. 52-84, 1978.<\/p>\n<p>12.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kiowski W, Rojas-Vigo AE, Julius S:\u00a0 \u201cHemodynamic studies of ticrynafen in hypertension\u201d, in: NM Kaplan (ed.), A New Class of Diuretics with Uricosuric Activity, A symposium developed from a clinical seminar.\u00a0 Postgraduate Medicine Communications, pp. 25-35, 1979.<\/p>\n<p>13.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Zweifler AJ, Nicholls MG:\u00a0 \u201cBeta-adrenergic blocking agents in the treatment of hypertension\u201d, in: E Rapaport (ed.), Cardiology Update \u2013 Reviews for Physicians.\u00a0 New York, Elsevier North Holland, pp. 329-346, 1979.<\/p>\n<p>14.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cHemodynamic evidence for central nervous involvement in mild hypertension\u201d, in: Y Yamori, W Lovenberg and ED Freis (eds.), Perspectives in Cardiovascular Research. Prophylactic Approach to Hypertensive Diseases.\u00a0 New York, Raven Press, pp. 309-314, 1979.<\/p>\n<p>15.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Quadir H, Gajendragadkar S:\u00a0 \u201cHyperkinetic state: A precursor of hypertension?\u00a0 A longitudinal study of borderline hypertension\u201d, in: F Gross and T Strasser (eds.), Mild Hypertension: Natural History and Management.\u00a0 London, Pittman Medical Publishing Co., Ltd., pp. 116-126, 1979.<\/p>\n<p>16.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cImportancia clinica de la hipertension arterial fronteriza\u201d, in: AG Caamano and LA Diaz-Barreiro (eds.), Hipertension Arterial, Mexico, Ediciones Medicas Actualizadas, S.A., pp. 309-316, 1980.<\/p>\n<p>17.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cThe psychophysiology of borderline hypertension\u201d, in: H Weiner, MA Hofer and AJ Stunkard (eds.), Brain, Behavior, and Bodily Disease.\u00a0 New York, Raven Press, pp. 293-303, 1981.<\/p>\n<p>18.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Simon G:\u00a0 \u201cMechanisms of antihypertensive action of beta-blocking agents.\u00a0 Lessons from a timolol trial\u201d, in: Proceedings of the Timolol Intercontinental Symposium.\u00a0 New York, Biomedical Information Corp., pp. 131-143, 1981.<\/p>\n<p>19.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cHypertension: clinical review\u201d, in: DL Parron, F Solomon and RJ Haggerty (eds.), Proceedings of Pharmacological and Psychosocial Treatment Approaches: Issues and Interrelationships.\u00a0 Washington, D.C., National Academy Press, 1981.<\/p>\n<p>20.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cBorderline hypertension\u201d, in: H Brunner and H Gavras (eds.), Clinical Hypertension and Hypotension.\u00a0 New York, Marcel Dekker, Inc., pp. 313-325, 1982.<\/p>\n<p>21.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cPsychophysiologic evidence for the role of the nervous system in hypertension\u201d, in: A Amery, R Fagard, P Lijnen and J Staessen (eds.), Hypertensive Cardiovascular Disease: Pathophysiology and Treatment.\u00a0 Boston, Martinus Nijhoff Publishers, pp. 217-230, 1982.<\/p>\n<p>22.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cHistoria natural de la hipertension arterial fronteriza sus repercusiones en la practica clinica\u201d, in: AG Caamano and LA Diaz-Barreiro (eds.), Hipertension Arterial.\u00a0 Mexico, Ediciones Medicas Actualizadas, S.A., pp. 183-189, 1982.<\/p>\n<p>23.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Hansson L:\u00a0 \u201cClassification of hypertension\u201d, in: J Genest, O Kuchel, P Hamet, M Cantin (eds.), Hypertension:\u00a0 Physiopathology and Treatment (2<sup>nd<\/sup>\u00a0ed.).\u00a0 New York, McGraw-Hill, pp. 679-682, 1983.<\/p>\n<p>24.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Hansson L:\u00a0 \u201cBorderline hypertension: epidemiologic and clinical implications\u201d, in: J Genest, O Kuchel, P Hamet, M Cantin (eds.), Hypertension: Physiopathology and Treatment (2<sup>nd<\/sup>\u00a0ed.). New York, McGraw-Hill, pp. 753-764, 1983.<\/p>\n<p>25.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Egan B, Julius S: \u201cBorderline hypertension\u201d, in: HR Black (ed.), Symposium on Hypertension in Office Practice, Primary Care, pp. 99-113, 1983.<\/p>\n<p>26.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Cottier C:\u00a0 \u201cBehavior and hypertension\u201d, in: TM Dembroski, TH Schmidt, G Blumchen (eds.), Biobehavioral Bases of Coronary Heart Disease.\u00a0 Karger Biobehavioral Medicine Series, Vol. 2, Basel, S. Karger AG, pp. 271-289, 1983.<\/p>\n<p>27.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Weder A, Egan BM:\u00a0 \u201cPathophysiology of early hypertension: implication for epidemiologic research\u201d, in: F Gross, T Strasser (eds.), Mild Hypertension: Recent Advances.\u00a0 New York, Raven Press, pp. 219-236, 1983.<\/p>\n<p>28.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cAntihypertensive treatment in borderline hypertension\u201d, in: HM Perry (ed.), Lifelong Management of Hypertension.\u00a0 Boston, Martinus Nijhoff, pp. 46-56, 1983.<\/p>\n<p>29.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cHypertension\u201d, in: S Julius (ed.), A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).\u00a0 Basel, S. Karger AG, pp. 1-7, 1984.<\/p>\n<p>30.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cStress and psychosomatic cardiovascular disorders\u201d, in: S Julius (ed.),\u00a0<u>A\u00a0<\/u>Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).\u00a0 Basel, S. Karger AG, pp. 17-23, 1984.<\/p>\n<p>31.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cType A behavior\u201d, in: S Julius (ed.), A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).\u00a0 Basel, S. Karger AG, pp. 24-29, 1984.<\/p>\n<p>32.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cPsychosomatic cardiovascular disorders and coronary-prone behavior\u201d, in: S Julius (ed.), A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).\u00a0 Basel, S. Karger AG, pp. 50-56, 1984.<\/p>\n<p>33.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Fitzpatrick MA, Egan B, Schneider R:\u00a0 \u201cNeural mechanisms in clinical hypertension\u201d, in: GP Guthrie, Jr. and TA Kotchen (eds.), Hypertension and the Brain.\u00a0 New York, Futura Publications, pp. 305-318, 1984.<\/p>\n<p>34.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Fitzpatrick MA, Julius S:\u00a0 \u201cThe role of the nervous system in the etiology and evolution of essential hypertension\u201d, in: GP Guthrie, Jr. and TA Kotchen (eds.), Hypertension and the Brain.\u00a0 New York, Futura Publications, pp. 319-325, 1984.<\/p>\n<p>35.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Ibsen H, Colfer HT.\u00a0 \u201cHemodynamic and pharmacologic correlates of plasma norepinephrine in hypertension\u201d, in: MG Ziegler and CR Lake (eds.), Norepinephrine-Vol. 2: Frontiers of Clinical Neuroscience.\u00a0 Baltimore, Williams &amp; Wilkins, pp. 401-409, 1984.<\/p>\n<p>36.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zweifler AJ, Julius S:\u00a0 \u201cMedical treatment of renovascular hypertension\u201d, in: JC Stanley, CB Ernst, and WJ Fry (eds.), Renovascular Hypertension.\u00a0 Philadelphia, W. B. Saunders Co., pp. 231-245, 1984.<\/p>\n<p>37a.\u00a0\u00a0\u00a0\u00a0 Julius S, Fitzpatrick MA:\u00a0 \u201cNeurogenic hypertension\u201d, in: TM Bayless, MC Brain and RM Cherniack (eds.), Current Therapy in Internal Medicine.\u00a0 Philadelphia, BC Decker, Inc., pp. 1231-1234, 1984.<\/p>\n<p>37b.\u00a0\u00a0\u00a0\u00a0 Julius S, Fitzpatrick MA:\u00a0 \u201cNeurogenic hypertension\u201d, in:\u00a0 RJ Glassock, Series Editor (ed.), Current Therapy in Nephrology and Hypertension.\u00a0 Philadelphia, B. C. Decker, Inc., pp. 340-344, 1984.<\/p>\n<p>38.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S.\u00a0 \u201cControversies in the research on hemodynamic mechanisms in the development of hypertension\u201d, in: MP Sambhi (ed.), Fundamental Fault in Hypertension, Developments in Cardiovascular Medicine.\u00a0 Boston, Martinus Nijhoff Publishers, pp. 263-275, 1984.<\/p>\n<p>39.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cImplications for hypertension\u201d, in: SM Weiss, KA Matthews, T Detre and JA Graeff (eds.), Stress, Reactivity, and Cardiovascular Disease.\u00a0 Proceedings of the Working Conference.\u00a0 Washington, USPHS, National Institutes of Health (Publication No. 84-2698), pp. 63-71, 1984.<\/p>\n<p>40.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Schneider R, Egan B:\u00a0 \u201cSuppressed anger in hypertension: facts and problems\u201d, in: MA Chesney and R Rosenman (eds.), Anger and Hostility in Behavioral and Cardiovascular Disorders.\u00a0 Hemisphere Publishing Corp, Washington, D.C., pp. 127-137, 1985.<\/p>\n<p>41.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Schneider R, Julius S, Moss G:\u00a0 \u201cPhysiological correlates of the type A coronary-prone behaviour pattern and the influence of metoprolol ( Lopressor): a preliminary report\u201d, in: A Zanchetti and P Turner (eds.), Towards Preventive Treatment of Coronary-Prone Behaviour.\u00a0 Hans Huber Publishers, Berne, Switzerland, pp. 42-48, 1985.<\/p>\n<p>42.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Weder AB, Hinderliter AL:\u00a0 \u201cDoes behaviorally induced blood pressure variability lead to hypertension?\u201d in: KA Matthews (ed.), Stress, Reactivity, and Cardiovascular Disease.\u00a0 New York, John Wiley &amp; Sons, Inc., pp. 71-82, 1986.<\/p>\n<p>43.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Egan B, Hinderliter A:\u00a0 \u201cAssessment of autonomic function in essential hypertension\u201d, in:\u00a0 RCA Frederickson, HC Hendrie, JN Hingtgen and MH Aprison (eds.), Neuroregulation of Autonomic, Endocrine, and Immune Systems.\u00a0 Boston, Martinus-Nijhoff, pp. 183-198, 1986.<\/p>\n<p>44.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Egan B:\u00a0 \u201cHemodynamics of hypertension\u201d, in: A Zanchetti, RC Tarazi (eds.), Handbook of Hypertension, Vol. 7: Pathophysiology of Hypertension \u2013 Cardiovascular Aspects.\u00a0 Amsterdam, Elsevier, pp. 153-178, 1986.<\/p>\n<p>45.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Egan BM, Julius S:\u00a0 \u201cCardiac reflexes and blood pressure elevation\u201d, in: FH Messerli (ed.), The Heart and Hypertension.\u00a0 New York, Cahners Publishing Company, pp. 11-19, 1987.<\/p>\n<p>46.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cHemodynamic, pharmacologic and epidemiologic evidence for behavioral factors in human hypertension\u201d, in: S Julius and DR Bassett (eds.), Handbook of Hypertension, Vol. 9: Behavioral Factors in Hypertension.\u00a0 Amsterdam, Elsevier Science Publishers, pp. 59-74, 1987.<\/p>\n<p>47.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Weder AB, Julius S:\u00a0 \u201cBehavior, blood pressure variability and hypertension:\u00a0 A research agenda\u201d, in: S Julius and DR Bassett (eds.), Handbook of Hypertension, Vol. 9: Behavioral Factors in Hypertension.\u00a0 Amsterdam, Elsevier Science Publishers, pp. 312-31, 1987.<\/p>\n<p>48.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cPathophysiology of hypertension \u2013 hemodynamic aspects\u201d, in: L. Hansson (ed.), The 1987 Hypertension Annual.\u00a0 London, Gower Academic Journals, pp. 37-56, 1987.<\/p>\n<p>49.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cBorderline hypertension\u201d, in: Hurst et al (eds.), Medicine for the Practicing Physician.\u00a0 Butterworth Publishers, Massachusetts, pp. 889-891, 1988.<\/p>\n<p>50.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cBorderline hypertension\u201d, in: Hurst, et al (eds.), Criteria for Diagnosis.\u00a0 Butterworth Publishers, Massachusetts, p. 304, 1989.<\/p>\n<p>51.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cHemodynamic assessment and pharmacologic probes as tools to analyze cardiovascular reactivity\u201d, in: N Schneiderman, SM Weiss and P Kaufmann (eds.), Handbook of Research Methods in Cardiovascular Behavioral Medicine.\u00a0 New York, Plenum Press, pp. 411-416, 1989.<\/p>\n<p>52.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Egan B, Julius S:\u00a0 \u201cThe hemodynamics of borderline hypertension\u201d, in: ME Safar and F Fouad-Tarazi (eds.), The Heart in Hypertension.\u00a0 Dordrecht, Kluwer Academic Publishers, pp. 47-66, 1989.<\/p>\n<p>53.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Petrin J:\u00a0 &#8220;Autonomic nervous and behavioral factors in hypertension&#8221;, in: JH Laragh and BM Brenner (eds.), Hypertension: Pathophysiology, Diagnosis, and Management.\u00a0 New York, Raven Press, pp. 2083-2090, 1990.<\/p>\n<p>54.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Johnson EH, Julius S:\u00a0 \u201cIs there a hypertensive coronary-prone personality?\u201d, in: F Buhler and J Laragh (eds.), Handbook of Hypertension, Vol. 13: The Management of Hypertension.\u00a0 Amsterdam, Elsevier Science Publishers, pp. 33-41, 1990.<\/p>\n<p>55.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Cox JP, Julius S, O\u2019Malley K, O\u2019Brien E: \u201cSelf-measurement of blood pressure\u201d, in Handbook of Hypertension.\u00a0 Amsterdam, Elsevier Science Publishers, pp. 112-125, 1991.<\/p>\n<p>56.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cRelationship between the sympathetic tone and cardiovascular responsiveness in the course of hypertension\u201d, in: EH Johnson, WD Gentry and S Julius (eds.), Personality, Elevated Blood Pressure, and Essential Hypertension.\u00a0 New York, Hemisphere Publishing Corporation, pp. 219-230, 1992.<\/p>\n<p>57.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cBorderline hypertension: Management\u201d, in: JL Izzo, Jr and HR Black (eds.), American Heart Association Hypertension Primer, Chapter E20, Dallas, American Heart Association, pp. 333-336, 1993.<\/p>\n<p>58.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Weder A, Julius S:\u00a0 \u201cPathophysiology of hypertension and treatment\u201d in: BN Singh, VJ Dzau, PM Vanhoutte and RL Woosley (eds.), Cardiovascular Pharmacology and Therapeutics, Chapter 57, New York, Churchill Livingstone Inc., pp. 861-883, 1994.<\/p>\n<p>59.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cEvolution of hemodynamic and neuroendocrine changes in the course of hypertension\u201d in FH Messerli (ed.), The ABC\u2019s of Antihypertensive Therapy, Chapter 3, New York, Raven Press, pp. 17-26, 1994.<\/p>\n<p>60.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Amerena J<strong>,<\/strong>\u00a0Julius S: \u201cRole of the nervous system in human hypertension,\u201d in NK Hollenberg (ed.) Atlas of Heart Diseases.\u00a0 Hypertension: Mechanisms and Therapy, Chapter 2, Philadelphia, Current Medicine, pp. 2.1-2.23 (Vol 1), 1994.<\/p>\n<p>61.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cThe changing relationship between autonomic control and haemodynamics of hypertension\u201d, in: JD Swales (ed.), Textbook of Hypertension.\u00a0 Oxford, Blackwell Scientific Publications, pp. 77-84, 1994.<\/p>\n<p>62.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Amerena J, Smith S, Petrin J:\u00a0 \u201cAutonomic nervous and behavioral factors in hypertension\u201d, in: JH Laragh and BM Brenner (eds.), Hypertension:\u00a0 Pathophysiology, Diagnosis, and Management.\u00a0 New York, Raven Press, pp. 2557-2569 (2<sup>nd<\/sup>\u00a0ed), 1995.<\/p>\n<p>63.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Amerena J<strong>,<\/strong>\u00a0Julius S: \u201cRole of the nervous system in human hypertension\u201d, in NK Hollenberg (eds.) Atlas of Heart Diseases.\u00a0 Hypertension: Mechanisms and Therapy, Chapter 2, Philadelphia, Current Medicine, 2.1-2.24 (2<sup>nd<\/sup>\u00a0ed), 1998.<\/p>\n<p>64.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S:\u00a0 \u201cManagement of borderline hypertension\u201d, in: JL Izzo, Jr and HR Black (eds.), American Heart Association Hypertension Primer, Chapter 150, Dallas, American Heart Association, pp. 433-436 (2<sup>nd<\/sup>\u00a0ed), 1999.<\/p>\n<p>65.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Amerena J, Julius S:\u00a0 \u201cNeurogenic hypertension\u201d, in RJ Johnson and J Freehally (eds.), Comprehensive Clinical Nephrology, Chapter 43, London, Harcourt Publishers Ltd., pp. 43.1-43.6, 2000.<\/p>\n<p>66.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Nesbitt S:\u00a0 \u201cEvolution of hemodynamic and neuroendocrine changes in the course of hypertension\u201d, in FH Messerli (ed.), The ABC\u2019s of Antihypertensive Therapy, Chapter 3, New York, Authors&#8217; Publishing House, pp. 13-23 (2<sup>nd<\/sup>\u00a0ed), 2000.<\/p>\n<p>67.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S: \u201cNeuroendocrine factors. \u00a0Role of sympathetic nervous and renin angiotensin systems\u201d, in MA Weber (ed), Hypertension Medicine, Chapter 7, Totowa, NJ, Humana Press Inc., pp. 89-97, 2001.<\/p>\n<p>68.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Amerena J<strong>,<\/strong>\u00a0Julius S: \u201cRole of the nervous system in human hypertension,\u201d in NK Hollenberg, E Braunwald (eds.) Atlas of Heart Diseases.\u00a0 Hypertension: Mechanisms and Therapy, Chapter 2, Philadelphia, Current Medicine, Inc., pp. 34-58 (3<sup>rd<\/sup>\u00a0ed), 2001.<\/p>\n<p>69.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Palatini P, Julius S: &#8220;Blood pressure and atherosclerotic risk factors,&#8221; in A Zanchetti (ed), Hypertension: Clinical Medicine Series, Chapter 1, England, McGraw-Hill International (UK) Ltd., pp. 3-11, 2001.<\/p>\n<p><a name=\"OLE_LINK1\"><\/a>70.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kjeldsen SE, Julius S, Weber MA, Stolt P: \u201cMain results from VALUE,\u201d in S Oparil, MA Weber (eds), Hypertension, Companion to Brenner &amp; Rector\u2019s The Kidney, pp. 376-380, 2005.<\/p>\n<p>71.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Kjeldsen SE, Julius S, Pedersen O, St\u00f6set O: \u201cRecent hypertension trials,\u201d in H Brunner (ed), The Year in Hypertension Volume 6, Chapter 1, Oxford, UK, Clinical Publishing, pp. 4-14, 2006.<\/p>\n<p>72.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<strong>Julius S:<\/strong>\u00a0\u201cHeart Rate and Hypertension,\u201d in: K Fox (ed), Slow the Heart, Beat the Disease. \u00a0Amsterdam, Elsevier Science Publishers, pp. 26-36, 2011.<\/p>\n<p>73.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<strong>Julius S<\/strong>, Feldstein CA: \u201cPrehypertension: definitions, clinical significance and therapeutic approaches \u2013to treat or not to treat?\u201d in AE Berbari, G Mancia, (eds) Special Issues in Hypertension.\u00a0 Milan, Springer Verlag Italia Srl, 3-12, 2012.<\/p>\n<p>&nbsp;<\/p>\n<p><u>Books or Journals Edited<\/u><\/p>\n<p>1.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Esler MD:\u00a0 The Nervous System in Arterial Hypertension, Springfield, Illinois, Charles C. Thomas, p. 476, 1976.<\/p>\n<p>2.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Hansson L, Julius S, Richardson PJ:\u00a0 Proceedings of the Timolol Intercontinental Symposium, (Stockholm, Sweden, October 27-28, 1979), New York, Biomedical Information Corporation, p. 456, 1981.<\/p>\n<p>3.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S (by invitation):\u00a0 A Comprehensive Guide to the Therapeutic Use of Trasicor (Pharmanual).\u00a0 Basel, S. Karger AG, p. 115, 1984.<\/p>\n<p>4.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Bassett DR:\u00a0 Handbook of Hypertension, Vol. 9:\u00a0 Behavioral Factors in Hypertension, Amsterdam, Elsevier Publishers, p. 352 , 1987.<\/p>\n<p>5.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Julius S, Chobanian A.\u00a0 Hypertension:\u00a0 A view beyond numbers.\u00a0 American Heart Journal 116, No. 1, Part 2, 1988.<\/p>\n<p>6.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Johnson EH, Gentry WD and Julius S:\u00a0 Personality, elevated blood pressure, and essential hypertension; Health Psychology and Behavioral Medicine, Hemisphere Publishing, 1992.<\/p>\n<p>7.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Zanchetti A, Hansson L, Rodicio JL, Julius S:\u00a0 Hypertension.\u00a0 McGraw-Hill International (UK) Ltd., London, 2001.<\/p>\n<p>8.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 van Zwieten PA, Julius S, AT<sub>1<\/sub>\u00a0blockers: are there alternative pathways reducing cardiovascular risk?\u00a0 Satellite symposium to ESH, Journal of Hypertension, 2001.<\/p>\n<p>9.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Mancia G, Chalmers J, Julius S, Saruta T, Weber M, Ferrari A, Wilkinson I:\u00a0 Manual of Hypertension.\u00a0 Churchill Livingstone, Harcourt Publishers Limited, London, 2002.<\/p>\n","protected":false},"featured_media":0,"template":"","vrste_clanova":[96],"razredi":[84],"_links":{"self":[{"href":"https:\/\/www.info.hazu.hr\/en\/wp-json\/wp\/v2\/clanovi\/20390"}],"collection":[{"href":"https:\/\/www.info.hazu.hr\/en\/wp-json\/wp\/v2\/clanovi"}],"about":[{"href":"https:\/\/www.info.hazu.hr\/en\/wp-json\/wp\/v2\/types\/clanovi"}],"version-history":[{"count":5,"href":"https:\/\/www.info.hazu.hr\/en\/wp-json\/wp\/v2\/clanovi\/20390\/revisions"}],"predecessor-version":[{"id":50404,"href":"https:\/\/www.info.hazu.hr\/en\/wp-json\/wp\/v2\/clanovi\/20390\/revisions\/50404"}],"wp:attachment":[{"href":"https:\/\/www.info.hazu.hr\/en\/wp-json\/wp\/v2\/media?parent=20390"}],"wp:term":[{"taxonomy":"vrste_clanova","embeddable":true,"href":"https:\/\/www.info.hazu.hr\/en\/wp-json\/wp\/v2\/vrste_clanova?post=20390"},{"taxonomy":"razredi","embeddable":true,"href":"https:\/\/www.info.hazu.hr\/en\/wp-json\/wp\/v2\/razredi?post=20390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}